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ABSTRACT
Toxicities of sulfur-based drugs have been attributed to formation of highly
reactive sulfur oxo-acids and depletion of glutathione by the formation of reactive
metabolites. Metabolic activation of these sulfur centers to conceivably toxic reactive
metabolites (RMs) that can covalently modify proteins is considered the initial step in
drug-induced toxicity. Despite considerable effort and research, detection and
characterization of these RMs during drug development and therapy remains a challenge.
Methimazole (MMI) and 6-propyl-2-thiouracil (PTU) are two commonly used
antithyroid, sulfur-based drugs. Though effective, these drugs are associated with
idiosyncratic toxicity. PTU has acquired a black box warning and physicians are calling
for its withdrawal. RMs resulting from bioactivation of these drugs have been implicated
in the aforementioned adverse reactions. Unfortunately, isolating and detecting RMs
using traditional analytical techniques has not been successful due to their high reactivity
and short life span, typically less than a minute.
Current approaches in drug metabolism studies use microsomal incubations to
generate RMs, which are then trapped using nucleophiles. Antithyroid drugs, however,
are known to deactivate enzymes involved in their oxidation. Moreover, due to the
complex nature of biological matrices and low abundance of possible toxic conjugates,
this technique results in poor selectivity and sensitivity. This study developed and
optimized an analytical method based on coupling electrochemical redox reactions and
mass spectrometry to generate, detect and identify RMs from antithyroid drugs. The
metabolites were also compared to those that were generated using chemical oxidants and
i

biological microsomes. Mimicry of enzymatic oxidation of the antithyroid drugs was
carried out by electrochemically oxidizing them using a coulometric cell coupled on-line
to electrospray ionization mass spectrometry (EC/ESI-MS). Oxidation of MMI and
subsequent trapping with nucleophile resulted in formation of adducts with Nacetylcysteine, revealing reactive metabolites. The most-postulated metabolite, sulfenic
acid, had never been isolated or detected until now, using electrochemistry on-line with
electrospray ionization. The results showed that bioactivation of MMI proceeds
predominantly through the S-oxide and not through formation of thiyl radicals. These
same trapping experiments were also conducted with PTU, but no conjugates were
detected. The lack of conjugates from PTU does not preclude formation of RMs, but
asserts radical pathway might be dominant in EC oxidation. A double mixing stopped
flow was used to investigate the kinetics and mechanism of reaction of the MMI and the
biologically relevant hypochlorous acid (HOCl), a product of oxidation of chloride (Cl-)
ions by myeloperoxidase. The products from the chemical oxidations were compared to
the electrochemically generated metabolites, some differences were apparent. Human
liver microsomes (HLM) were also used, to investigate oxidation of PTU. Oxidation of
PTU, resulted in the supposedly toxic S-oxide, but this has never been isolated, save for
speculation. A comparison of metabolites that were found with HLM to those generated
electrochemically showed some degree of similarity. These results show that in vitro
techniques such as chemical oxidations and electrochemistry coupled to mass
spectrometry can be used to mimic oxidative metabolism and subsequent high throughput
screening of reactive metabolites.
ii
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CHAPTER ONE
INTRODUCTION AND RATIONALE
Drugs undergo different phase I biotransformations such as oxidations,
reductions, hydrolysis, hydration and condensation followed by phase II conjugation
reactions such as glucuronidation which results in detoxification.1,2 Oxidative reactions
catalyzed by cytochrome CYP450 enzymes forms the bulk of these biotransformations.3
The enzymatic biotransformation of drugs and xenobiotics usually results in
detoxification and subsequent elimination of the drug metabolites from the body.4
However, in some cases, the drugs are bioactivated to toxic reactive metabolites.5
Reactive metabolites have been found to play a major role in drug-induced toxicity,
leading to adverse drug reactions.6 These transient metabolites are electrophilic in nature
and have the capacity to bind covalently and irreversibly to cellular macromolecules
resulting in formation of haptens.7 These can then induce drug adverse events such as
direct target damage e.g., liver injury or immune mediated toxicity.8
ADRs rank between 4th and 6th leading cause of death and results in withdrawal of
drugs from the market.9-11 These adverse drug reactions can be classified as either
idiosyncratic (unpredictable) or intrinsic; which are non-idiosyncratic (predictable), as in
the case of liver injury due to acetaminophen overdose as they are dose dependent.12,13
Utrecht defined idiosyncratic toxicities as adverse drug reactions that do not occur in
most patients and do not involve the known pharmacological effects of a drug.14 Several
drugs have been withdrawn from market or from use after reports of hepatotoxicity were
noted .15-18 Some of them have been in use for years e.g., the anti-diabetic troglitazone,19
1

talcapone, trovafloxacin20 and the anti-inflammatory drug (NSAID) sudoxicam21. The
common feature with all these drugs was their bioactivation to reactive metabolites
during metabolism.
Although there has been extensive research in the ﬁeld of chemical toxicology;
reliably predicting the occurrence of idiosyncratic adverse drug reactions (IADRs) still
remains elusive22. Three main hypotheses have been suggested to explain how reactive
metabolites might induce immune-mediated idiosyncratic reactions. These are the hapten
hypothesis, the danger hypothesis, and the pharmacological interaction (PI), as shown in
Figure 1.1, below. The PI’s hypothesis suggests that drugs which lack hapten
characteristics actually bind covalently and irreversibly to cell receptors resulting in an
immune response.23,24

2

Figure 1.1 Hypothesis in etiology of drug induced liver injury. Adapted from Deng et al
Pharmacol Rev 61:262–282, 200925

The current understanding of IADRs indicates that there are several
molecular/cellular mechanisms that are not mutually exclusive and can arise from either
direct or off-target effects either from the parent drug or its metabolites14,25 as shown in
figure 1.1. Although the relationship between idiosyncratic adverse reactions and reactive
metabolites is not well established, evidence in figure 1.1 and other sources show that
drugs and their reactive metabolites are involved at the onset of idiosyncratic toxicities.263

29

In general, the formation of reactive metabolites in drug metabolism is considered

unsafe.30 Therefore it is important to understand mechanisms by which bioactivation
occurs for the purpose of screening and structural characterization of metabolites in order
mitigate the risk associated with these reactive metabolites during drug design and even
during therapy. This will go a long way in reducing attrition rates in drug development.
1.1 Methods for characterization of reactive metabolites

Toxicity of drug candidates contributes about 21% towards failure of lead drug
candidates during development.31,32 As mentioned above, the major culprits are the
unexpected and sometimes reactive metabolites. Different methods have been employed
in screening and characterization of reactive metabolites. Techniques using mass
spectrometry have become the workhorse in drug development and discovery.33 Current
methods to detect and identify reactive metabolites are based on indirect measurements
by mass spectrometry.34 The reactive metabolites from bioactivation of drugs are
electrophilic and sometimes radical in nature.7 These metabolites are short-lived, with
half-lives of usually less than 1 minute, and are not normally detectable in plasma or
urine,35 but they can be detected as phase II conjugates.36 Most reactive metabolites can
be captured by trapping them with nucleophiles such as N-acetyl cysteine, methoxyl
amine and GSH to form stable adducts in microsomal incubations.37 The trapped
conjugates are usually analyzed using a combination of liquid chromatography and
tandem mass spectrometry (LC/MS/MS). Other techniques such as infrared spectroscopy
(IR) and NMR may also be used for full structural elucidation. A slightly similar method
of trapping and identifying the conjugates uses radiolabeled compounds such as [35S]
4

cysteine, [14C] sodium cyanide and [35S] glutathione.38 However, this is a low
throughput technique and is also expensive, which makes it unsuitable during lead
optimization.39 Measurement of covalent binding to liver microsomal proteins in
presence and absence of NADPH is another method that is used to screen for
metabolites.40
1.2 Electrochemistry/liquid chromatography/mass spectrometry (EC/LC/MS) in
drug metabolism

The conventional method of studying oxidative drug metabolism during preclinical
experiments is through animal models (in vivo) or perfused organs in vitro.41 However,
the use of animals in experiments involving scientific research and biological testing has
raised concerns over the years among animal advocates.42 In view of this as well as the
large number of drug candidates emerging and those existing, there has been a renewed
interest in the development of complementary tools for mimicry of oxidative metabolism.
Although it remains a challenge to extrapolate data generated from such systems to actual
in vivo systems, these biomimetic tools offer some advantages that are not inherent in the
conventional methods.
Electrochemistry coupled on-line to liquid chromatograph/mass spectrometer
(EC/LC/MS) has the potential to mimic redox metabolism. Research has shown that
electrochemistry can be coupled to mass spectrometer in order to detect products of
oxidation. 43-48 The EC/LC/MS method offers the advantage of generating and isolating
reactive metabolites in the absence of physiological endogenous material, where usually
5

the endogenous matrix components will immediately bind to the reactive metabolites
resulting in evasion of detection.49-51 Jurva and co-workers reported that reactions such
as N-Dealkylation, S-Oxidation, P-Oxidation, alcohol oxidation and dehydrogenation that
proceed via a mechanism initiated by single electron transfer or hydrogen abstraction are
amenable to electrochemical oxidation.52 Therefore EC/LC/MS can be used to mimic
biotransformation, synonymous to CYP450’s. Different experimental setups can be used;
a column may be used between the cell and the mass spectrometer, for purification if
needed. However, this may slow the time taken by metabolites to be detected from mass
spectrometer.
1.3 Bioactivation of Sulfur based drugs

Microsomes contain both flavin-containing monooxygenases (FMO) as well as
CYP450’s. CYP450’s are usually involved in bioactivation of drugs, through oxidative
metabolism53. They both use molecular oxygen and NADPH for the oxidation of
substrates (S).
S + O2 + 2e + 2H+  SO + H2O ……………. (1)
The bulky of oxidation process is simply insertion of oxygen on to the substrate. Our
research in the past has focused on investigating the mechanism of S-oxidation of
organosulfur compounds.54,55 Extensive studies from our laboratory have shown that
nearly every organosulfur compound presents a unique reactivity and no generic
oxidation pathway can be easily derived. The sulfur atom has been implicated as a site of
6

bioactivation, resulting in formation of reactive and potentially toxic metabolites from
bioactivation of sulfur containing drugs.56 Many of the adverse reactions produced by
penicillamine and other compounds with an active sulfhydryl group form a distinctive
pattern when viewed as a class. Alterations in taste perception, mucocutaneous lesions,
proteinuria due to immune-complex membranous glomerulopathy, and pemphigus are
adverse reactions that have been encountered with all of these compounds. Classic
examples include the thiol, captopril, a still-used antihypertensive drug which comes with
a black box warning and is associated with hepatotoxicity.57-59 It can only be used in low
doses and after careful selection of patients to avoid idiosyncratic drug reactions and thus
cannot be used for patients with severe hypertension.58 Troglitazone, a thiazolidinedione,
developed for diabetes mellitus type 2, had to be withdrawn from market because it
caused severe liver injury. Thiazoles such as Sudoxicam were withdrawn in Phase III
trials when it was already apparent that the drug was rife with IDR’s; while a closelyrelated drug, Meloxicam, has not been associated with any IDR’s. This study
investigates the bioactivation of two sulfur based drugs, methimazole and 6-propyl-2thiouracil. These two drugs are used as antithyroid drugs. Bioactivation of thionamides to
reactive intermediates have been implicated in adverse drug reactions. Thionamides
drugs are associated with idiosyncratic toxicity, characterized by skin reactions,
leucopenia, agranulocytosis, aplastic anemia, hepatitis and cholestasis.60

7

1.4 Mechanism of action of antithyroid drugs

Peroxidases oxidize iodides in the presence of H2O2 to form I+ ions, which in the
presence of this enzyme, binds to thyroglobulin.61 6-propy-2-lthiouracil (PTU) and
methimazole (MMI) block the thyroid hormone synthesis by inhibiting the thyroid
peroxidase (TPO) or diverting oxidized iodides away from thyroglobulin.
1.5 Significance of this research

This research has the potential of being informative on the design of in vitro
experiments, and to refine as well as reduce in vivo animal trials. This is crucial in early
drug development and can be used to weed out unsuitable candidates for further
development, thus reducing late stage compound failures. This technique can be adopted
by the pharmaceutical industry as an alternative or complementary technique to existing
screening methods. Successful isolation and synthesis of additional/novel reactive
metabolites can enhance further studies in bioassays and toxicological studies. This will
also add value in understanding the generation of reactive metabolites, for example, the
long speculated sulfenic acid responsible for hepatotoxicity in oxidation of methimazole
was first reported as part of this work.62 Further development of this method can lead to
automation and thus reduce the time required for analysis. Apart from metabolism, this
technique has potential to be used as an analytical tool for detection and determination of
other compounds or drug concentrations; e.g., in plasma samples, as electrochemistry is a
sensitive technique that can be used at very low concentrations.

8

CHAPTER TWO
INSTRUMENTATION, MATERIALS AND METHODS
2.1 INSTRUMENTATION
2.1.1 Electrochemical apparatus

Figure 2.1 Basic potentiostat circuit and a three-electrode cell, [Courtesy of Gamry
Instruments® application notes]

Figure 2.1, above shows a basic three electrode cell (sensor) that utilizes a
potentiostat hardware, which is used to control the electrode cells for running
electroanalytical experiments. The electrode cell is composed of a working electrode
9

(WE), whose function is to serve as a platform on which the electrochemical reaction
takes place. The second electrode is the reference electrode (RE), its function is to
measure any potential quantity present in WE electrode.63 A third electrode, the counter
electrode (CE) completes the circuit. Its sole purpose is to conduct current into or out of
the cell. This current has to exactly balance the current generated at the working
electrode. Cyclic voltammetry was used in the initial phase of these experiments, to
optimize the technique of coupling electrochemistry to mass spectrometry. Were the
oxidation potential of an electroactive compound in a given medium was not known,
preliminary studies were conducted using cyclic voltammetry which gave an insight on
the required optimum potentials. Despite the difference between cyclic voltammetry and
the technique that was mostly used here, the electrochemical apparatus have similar
design and same principle of operation as the cell shown above, except that the analyte
flows through the working electrode, vide infra. The ESA Coulochem III® MultiElectrode Detector used here is equipped with the DC Potentiostat Board as well as
Pulse/Scan Potentiostat Board. The analogue signals were controlled by electronic
circuits, in the logic module.64
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2.1.2 LTQ-orbitrap Electrospray-Ionization Mass Spectrometry (ESI-MS)

Figure 2.2. Schematic diagram of LTQ- Orbitrap Mass Spectrometry [Courtesy of
Thermofisher Scientific Application Notes]

Mass spectra of the electrochemical oxidation metabolites were acquired on a
high-resolution (m/Δm = 30 000) Thermo Scientific LTQ-Orbitrap Discovery mass
spectrometer (San Jose, CA) equipped with an electrospray ionization source. Figure 2.2
shows a schematic diagram of an LTQ-orbitrap mass spectrometer. It is a hybrid
instrument that combines the linear trap and orbitrap thus making it more robust in
detection, identification, and characterization of samples, including biological
complexes.65,66 It has high mass accuracy, high resolving power, high sensitivity and MSn
capability, although tandem mass spectrometry was not utilized in these
experiments.67 The instrument above uses electrospray ionization for its ion source. See
figure 2.3 below.

11

Figure 2.3: Schematic representation of electrospray ionization source68

Electrospray ionization (ESI) is a soft ionization technique used for production of
gas phase ions, without fragmentation of the molecule being observed. Figure 2.3 shows
an ESI process, the transfer of ionic species from solution into the gas phase by ESI
involves three steps: (a) dispersal of a fine spray of charge droplets, (b) solvent
evaporation and (c) ion ejection from the highly charged droplets.68 The charged droplets
generated at the exit of the electrospray tip pass down a pressure and potential gradient
toward the linear trap analyzer, then into the C-trap where the ions are cooled and slowed
down, then into another analyzer, the orbitrap, and finally to the detector.69 The mass
spectrum is a graphical display of the relative abundance of ion signals against the m/z
ratios. It is a common practice that the highest signal is taken as 100% abundance and all
the other signals are expressed as a percentage of this peak. Details of full operation of
each component of the mass spectrometer are described elsewhere in literature.70
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2.1.3 Coupling electrochemical apparatus to LTQ Orbitrap MS

GSH

Figure 2.4. Schematic of EC/ESI –MS system. Coulochem III Electrochemical Detector®
controls potential of the flow through cell.

A schematic representation of EC-MS coupling is shown in Figure 2.4. ESA
Coulometric cells 5150 and 5021A or 5130 and 5021A were interfaced to an LTQ
Orbitrap mass spectrometer. The potential to the cells was controlled using a potentiostat
in the form of an ESA Colouchem III detector. This unit has a front panel with key
controls to input and change different parameters such as potential and current output.
The cells described above are equipped with a flow through graphite working electrode,
solid-state palladium (Pd/H2) reference electrode and a palladium counter electrode.64
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Solutions of analytes and electrolytes were infused into the flow through cells using a
syringe pump at different flow rates, depending on the requirements of the experiment.
In trapping experiments, the effluent from the cell was directed into a T-junction where it
would be mixed with a trapping solution also pumped from another syringe pump into
the mass spectrometer.
Coupling electrochemistry techniques to a mass spectrometer is not trivial and is
not common. Several practical aspects have not yet been fully explored. Optimum
coupling conditions are required for EC/MS technique. Electrospray Ionization Mass
Spectrometry is associated with high voltage at the ionization source, for example the
spray voltage used during positive mode experiments was +4.5 kV. This can result in
backward electric currents flowing through the electrolyte into the cell and detector. The
magnitude of this current can be large and dangerous resulting in electric shock to the
operator as well as damage to the cells and detector. In order to avoid this, a ground point
was introduced between the mass spectrometer and the electrochemical equipment. Online experiments coupling the cell to mass spectrometer were performed with a
decoupling union kit that was used to ground and decouple the high voltage from the
ESI- MS as shown in Figure 2.4. Optimum performance of the above setup was realized
with ESI source parameters set as follows: spray voltage, 2.5 kV in negative mode and
4.5 kV in positive mode; spray current, 1.96 (μA); sheath gas flow rate, 20 L/min;
auxiliary gas flow rate, 0.01 L/min; capillary voltage, −16 V; capillary temperature, 300
(°C); and tube lens, −115 V. Detection was carried out in both the negative and positive
ionization mode (−ESI) for 4 min. The detection parameters were set up as follows:
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Analyzer: FTMS, positive and negative polarity; mass range, normal; resolution, 30 000;
scan type, centroid.

2.1.4 Nuclear Magnetic Resonance (NMR) Spectroscopy

Nuclear magnetic resonance spectrometry (NMR) spectroscopy was also used in
structural characterization and verification of products and intermediates. However, it
was of little use in EC-MS experiments. Stability of reactive intermediates is dictated by
local environment. After lyophilizing and purifying the products for NMR analysis, there
were changes in environment and morphology, hence intermediates were not observed in
NMR spectra. By their nature the intermediates are short lived and isolating them is not
trivial. Hence we tried to do a real time analysis. NMR results obtained showed mostly
substrate, even after oxidation, it is as expected since the S-OH bond is unstable. NMR
experiments described above were conducted using a Bruker AMX-400 MHz Nuclear
Magnetic Resonance (NMR) spectrometer. The atomic nucleus is a spinning charged
particle, and it generates a magnetic field.

2.1.5 Conventional UV/Vis Spectrophotometry

Kinetics and reaction dynamics were carried out using spectrophotometric
techniques. Slow reactions that occurred in more than sixty seconds were measured using
a Perkin Elmer Lambda 25 UV/Vis spectrophotometer system within the range 200 to
800 nm. For these instruments, holographic grating was used as the monochromator and
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two radiation sources, a deuterium lamp (UV) and a halogen lamp (visible range) were
used in sequence as the polychromator light sources. The Perkin Elmer
spectrophotometer was interfaced to a desktop computer and uses the UV WinLab
Software for data collection and analyses. Path length of the cuvette was 1 cm. Constant
temperature was maintained by use of a circulating water bath attached to the cell
holders.

2.1.6 Stopped Flow Spectrometry

Figure 2.5. Sample Handling Unit (SHU) flow circuit diagram for SF-61DX2 Hi Tech
Kinet Asyst Stopped flow Spectrometer. [Courtsey of Hi- Tech Scientific Operators
Manual]
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Rapid reactions with time scales of less than 10 seconds were measured using the
stopped-flow technique, which can follow reactions with time scales as short as 1
millisecond. The Hi-Tech Scientific SF61 – DX2 Double mixing stopped-flow
spectrophotometer was used for the acquisition of absorbance data, it allows for changes
in optical properties as a result of reactions to be monitored using UV/VIS. A stable
Xenon Arc lamp was used as the light source. The instrument was interfaced to a desktop
computer via a 413 kHz 16 bit A/D converter to enable the conversion of analog data to
digital form. Small volumes of solutions are driven from high performance syringes
through a high efficiency mixer(s). The sample handling unit (Figure 2.5) facilitates both
the single mixing of two reagents, using only one of the drives, and double mixing of
three reactants by a push-push mode of operation. However, experiments were conducted
in single mixing mode. Double mixing mode enables transient species formed by mixing
reactants in A and B to be subsequently mixed with a third reactant, C, after a delay
period. Reactant reservoir D is reserved for the buffer and this will push the premixed
solutions A and B (from mixer 1) to a second mixer (mixer 2) where it reacts further with
reactant C. The resultant mixture passes through a measurement flow cell and into a
stopping syringe where the flow is stopped. Just prior to stopping, a steady state flow is
achieved. As the solution fills the stopping syringe, the plunger hits a block, causing the
flow to be stopped instantaneously, and an absorbance is then recorded. 73
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2.2 MATERIALS AND METHODS
2.2.1 Chemicals

Reagent grade methimazole, 6-propyl-2-thiouracil,(PTU) reduced glutathione, Nacetylcysteine and methoxylamine, perchloric acid and sodium perchlorate,
acetaminophen, reduced glutathione, acetic acid, and ammonium acetate were obtained
from Sigma Aldrich and were used without further purification.. Ammonia, methanol
and formic acid, ammonium acetate, acetic acid, sodium formate, acetonitrile, phosphate
monobasic and phosphate dibasic were from Fischer Chemicals. Water for all
experiments were purified using a Barnstead Sybron Corp. water purification unit capable
of producing both distilled and deionized water (Nanopure ). Solvents used for
electrochemical oxidation and mass spectrometry were HPLC grade. Human liver
microsomes, rat liver microsomes, NADPH regenerating system were obtained from
Corning.

2.2.2 On-line EC/ESI-MS electrochemical oxidation of Analytes

Experiments were carried out in acidic, neutral and alkaline medium. The
analyte was dissolved in acidic medium which consisted of 20 % methanol with 80 % 20
mM formate buffer ( pH 2.75). For neutral medium, a combination of 20 % methanol
with 80 % 50 mM phosphate buffer (pH 7.4) was used. Alkaline media utilized a 20 %
methanol with 80% 20mM ammonium buffer solution (pH 10.2). A 500 µL sample was
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infused through the electrochemical cell at a flow rate of 10 µL/min before the cell was
turned on. With the cell turned on, species generated from oxidation in each medium
were monitored on the mass spectrum generated on-line. The potential was changed
manually on the front panel of control module of ESA Coulochem III Electrochemical
detector from 100 mv to 1200 mv. Each scan acquisition lasted for four minutes. The
optimum potential was determined first before acquiring data.

2.2.3 Experimental procedure for trapping experiment

A 100 µM sample of analyte in suitable electrolyte-solvent system was infused
through the electrochemical cell at a flow rate of 10 µL/minute. A solution of containing
the nucleophile (e.g. N acetyl cysteine) 500 µM from another syringe was then infused at
the same rate. The effluent from both channels combined and mixed at a T-junction
flowed into the cavity of mass spectrometer as shown in Figure 2.4.
2.2.4 Purification and standardization of chlorite

Commercially-available sodium chlorite varied in purity (78−88%), with the main
impurities being chloride and carbonate. The sodium chlorite was recrystallized once
from a (1:1:1) water/methanol/acetonitrile mixture to bring the assay value to 96%. These
were stored in a desiccator in small batches of 5 g or less to avoid possible explosions.74
The recrystallized chlorite was standardized iodometrically by adding excess acidified
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potassium iodide and titrating the liberated iodine against sodium thiosulfate with freshly
prepared starch as an indicator as described previously.75 Chlorine dioxide was prepared
by the standard method of reducing sodium chlorate in a sulfuric acid/oxalic acid
mixture.76 The stream was passed through a sodium carbonate solution before being
collected in ice-cold water at 4 °C at a pH of ∼3.5. Standardization of ClO2 was also
accomplished by iodometric techniques through the addition of excess acidified
potassium iodide and back-titration of the liberated iodine against standard sodium
thiosulfate. The chlorine dioxide was stored in an acidic medium in a volumetric flask
wrapped in aluminum foil at 4 °C. Chlorine dioxide was also standardized jointly by its
molar absorptivity coefficient (ε) of 1265 M−1 cm−1 at 360 nm on a PerkinElmer Lambda
25S UV/vis spectrophotometer.

2.2.5 Reaction Dynamics

Kinetics experiments were carried out at 25 °C and at an ionic strength of 1.0 M
(sodium perchlorate). The ClO2 −/ClO2/ MMI reactions were monitored
spectrophotometrically at λ = 360 nm, as the reactions were performed in excess chlorite
in order to utilize formation of chlorine dioxide as an indicator of reaction progress.
Reactions monitoring consumption of MMI were monitored at 260 nm, where MMI has
its strongest absorption peak. Kinetics measurements were performed on a Hi-Tech
Scientific double-mixing SF-61DX2 stopped-flow spectrophotometer. Stoichiometric
determinations were carried out by mixing various ratios of chlorite and MMI (in an
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acidic medium to avoid alkaline disproportionation of ClO2) in stoppered volumetric
flasks and scanning them spectrophotometrically for the formation of ClO2 after an
incubation of up to 2 days. Qualitative and quantitative analysis of the sulfate produced
was performed through its precipitation as BaSO4. For reactions run under excess
chlorite conditions, the excess oxidizing power was evaluated by the addition of excess
acidified iodide, which was titrated against standard thiosulfate with freshly prepared
starch as an indicator.

2.2.6 Microsomal enzymatic oxidation

Human liver microsomes were obtained from Corning. A well-established
protocol for microsomal incubation (provided from Corning upon purchase of the
microsomes) was followed with minor changes to suit the experiment and substrates
involved. The microsomal fractions were stored at -80 oC and thawed immediately before
each experiment. The following quantities were used. Initially, 713 µL of purified water,
200 µL of 0.5 M potassium phosphate buffer pH 7.4, 50 µL NADPH regenerating
system solution A (solution A contains NADP+ and Glucose-6-phosphate), 10 µL
NADPH Regenerating system solution B ( Solution B contains Glucose-6-phosphate
dehydrogenase) 2 µL substrate in solvent, making a final substrate concentration of
10µM, were combined before adding microsomes. When combined solution A and B
provide the regenerating system for all NADPH requiring oxidase assays. After warming
in a 37oC water bath for five minutes, the reaction was then initiated by adding 25
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µL(0.5 mg ) liver microsomes and then was mixed and returned to a 37 oC water bath.
After 60 minutes a 100 µL aliquot from the incubation was withdrawn and the reaction
was terminated by adding 100 µL acetonitrile. This was then mixed and placed on wet
ice followed by centrifuging at 10,000 Xg for three minutes. The supernatant from the
protein pellets was withdrawn for analysis using LC/MS. Incubations without NADPH
and microsomes were used as controls, to ensure that formation of metabolites was
dependent on HLMs and NADPH.

2.2.7 LC-MS analysis.

The metabolites produced by incubation of PTU, were collected and analyzed by
LC-MS. The separation of the metabolites was achieved using a reverse phase Zorbax
Eclipse Plus 3.5µm, C8 column. Colum dimensions were as follows: 100 mm x 2.1 I.D.
The flow rate was set at 200µL/min and the injection volume was 20 µL/min. The
gradient separation was performed by two solvents. Mobile phase A: 0.1 % acetic acid in
water and mobile phase B: 0.1 % acetic acid in methanol. The applied gradient profile
was 10 % B for 5 minutes, followed by 30 % for another 5 minutes, and then 50 : 50 for
two minutes and finally 90% B for the last six minutes. The column was operated at
35oC. The MS based detection was carried out it positive ion mode using both FTMS
and ITMS detection
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2.2.8 Structural elucidation, mass accuracy and theoretical m/z calculations
High resolution mass spectrometry allowed calculation of mass accuracy with a
relative error of less than 4 ppm, providing unequivocal identification of metabolites.
Hence, the exact nature of modification of the metabolites was elucidated, eliminating
possibilities of false positives, which results during identification of metabolites. High
resolution MS data-processing and calculation of elemental compositions were carried
out using the Qual browser of Xcalibur SR2 Thermo Fisher Scientific. Xcalibur™
software was used to arrive at the proposed structures. For example, the elemental
composition calculator in Xcalibur™ returns 10 possible elemental compositions within
+/- 100 ppm for the measured mass at m/z 129.01143 (See figure 2.6) giving all plausible
chemical compositions hence structures for that peak, within that mass tolerance. When
the mass tolerance was within +/- 4 ppm (high accuracy); only one composition
combination was possible, figure 2.7. In addition, even electron ions are assumed since
electrospray ionization (ESI) was used for ion generation. Simulation of the proposed
elemental compositions under the measured spectrum was also used in mining possible
chemical formula for the major ions77 (Figure 2.8). ChemBioDrawTM was used in
obtaining exact masses for the proposed structures and calculation of mass accuracy from
exact versus observed masses, with five decimal places. Mass tolerance for reported
structures was within +/- 4 ppm, giving high mass accuracy and an unambiguous
assignment of the peaks.78
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Figure 2.6: Qual BrowserTM showing simulation for elemental composition using
Xcalibur™, calculator, showing 10 possible composition at low accuracy of +/- 100
ppm.
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Figure 2.7: Qual BrowserTM showing simulation for elemental composition using
Xcalibur™, calculator, showing only one possible composition at high mass accuracy
of +/- 4 ppm.

25

MMI127TF #6-26 RT: 0.08-0.28 AV: 21 NL: 4.67E6
T: FTMS + c ESI Full ms [110.00-300.00]
129.01140
C 4 H5 O N2 S

100

146.03813
C 4 H8 O N3 S

95
90
85
80
75
70

Relative Abundance

65
60
55
50
45
40
35
30
25

115.03213
C 4 H7 N2 S

20
15

137.01401
C 3 H7 O3 N S

147.02205
144.92715 C 4 H 7 O 2 N 2 S
148.03376
C 4 H3 O N S 2
C H4 O3 N6
141.09071 142.94773
C 8 H 13 O 2 H O 6 N S

136

140

10
5 111.11638 114.02422 116.10658
C 8 H 15 C 4 H 6 N 2 S C 4 H 12 N 4
0
110
112
114
116
118

120.96569 123.05484
C 2 H3 O N S 2 C 7 H9 O N
120

122

124

131.00714
C H O3 N5

127.97907
C 5 H4 S 2
126

128

130
m/z

132

134

138

142

144

146

148

150

Figure 2.8: Simulation of the proposed elemental compositions under the measured
spectrum confirming chemical formula for the major ions.
By exploiting the capability of LTQ-OrbitrapTM and the Qual BrowserTM software
which gives exact mass measurement at high resolution,79 it was able to identify
modifications on analyses. These software allows identifications of small molecules, even
in complex endogenous matrix with microsomes, this has become standard practice in
drug development.80
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2.3 OPTIMIZATION OF PARAMETERS
2.3.1 Optimization of electrochemical methods

The most important part of developing this technique was to optimize it with drug
whose behavior is well established. In the electrochemical cell used in these studies, the
conversion rate of analytes to metabolites was affected by flow rate, pH of the electrolyte,
and nature of the analyte as well as the potential applied to the electrochemical cell48.
APAP is oxidized into well-known hepatotoxic (n-acetyl-p-benzoquinoimine) NAPQI
which forms conjugates with thiols such as GSH and N-acetyl-l cysteine81.
Electrochemical properties of acetaminophen (APAP) are well characterized and
documented in literature, hence APAP was chosen as the test compound in order to
optimize the method.48,82 Getek et al, successfully coupled the coulometric cell to a mass
spectrometer and were able to detect APAP conjugates with glutathione and cysteine81.
Formation of its reactive metabolites and their subsequent conjugation with glutathione is
also well established. A number of studies using cyclic voltammetry reported that APAP
is oxidized to the reactive metabolite N acetyl-p- benzoquinone imine (NAPQI).83,84
Cyclic voltammetry was used initially to determine oxidative potential of APAP.
Potentials between 450 mV- 650 mV with respect to Pd/H2 electrode, were established to
be optimum oxidation potential for acetaminophen. Different pH conditions, solvents
and potentials were tested as described in literature. The parameters described in
literature were modified in order to suit the available equipment. For cyclic voltammetry
the optimum pH was found to be 6.4.
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2.3.2 Sample preparation and delivery

A 10 µM solution of APAP solution in 20 mM ammonium acetate, pH 6.4 in 20
% aqueous methanol, was infused into the Dionex synthesis cell model 5051 using a
syringe pump at flow rate of 10 µL/min. The effluent from the cell was directed into a Tjunction where it was mixed with a solution of 50 µM GSH, also pumped at a rate of 10
µL/min from another syringe pump into the mass spectrometer. The flow-through
coulometric cells used here were associated with high back-pressure and clogging,
resulting in leakages in the system and breaking of the gas tight syringes, stalling
experiments. Instead of using a micron filter that was connected to cell, to prevent fouling
and clogging of electrodes, the solutions were filtered off-line before being introduced to
the cell. Using the cell without the micron filter reduces back-pressure therefore leakages.
Plastic syringes were used versus gas tight glass syringes. Although using gas tight, glass
syringes sounds convenient, under compressive stress glass syringes were easily breaking
as opposed to plastic syringes that would yield and bend. Thus high flow rates above
50µL/min resulted in high back pressure, subsequent breaking and leaking. These
parameters were optimized during this phase. Optimum flow rates were found to lie
below 40 µL/min. The syringe pump on the Orbitrap could only be used with flow rate of
10 µL/min thus reducing the pressure. Despite the limitation imposed by flow injection,
lower flow rates resulted in higher conversion of analytes into metabolites, due to the
extended residence time in the cell. Effect of residence and ageing times of analytes in
the cell were also determined during optimization stage.
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2.3.3 Results and discussion from optimization

Figure 2.9 shows the mass spectrum obtained from oxidation of APAP at 650 mV
vs Pd/H2 solid state reference electrode and its reaction with GSH. The most dominant
peaks at m/z 152 is due to acetaminophen [M+H+] and m/z 308 is GSH [M+H+]. The next
largest peak at m/z 615 was generated by GSH disulfide (GSSG). Shayani-Jam and coworkers suggested that (N-acetyl-p-benzoquinone imine) NAPQI has a catalytic role in
which it reacts with GSH rather than in formation of the APAP-GSH adduct as reported
in previous publications, thus the process mimic phase I and phase II drug
metabolism.48,81 They proposed that this reaction will result in oxidation of GSH to
glutathione disulfide (GSSG) while reducing NAPQI to APAP again, without formation
of the adducts as shown in Figure 2.10 implying the adduct is not the major product.
This suggestion appears to agree with the low yield of adduct that was experimentally
observed during the electrochemical oxidation of APAP.
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Figure 2.9: ESI (+) mass spectrum of APAP and GSH mixture, after APAP oxidation at
650mv vs Pd/H2.
Interestingly, the mass spectrum obtained, resulting from coupling the
electrochemical cell to a high resolution and high mass accuracy orbitrap had both adduct
and GSSG dimer, albeit in low concentrations. This shows that these two methods are
synergistic and complementary to each other. It is important to note that the GSH was not
incubated with analyte that was passed through the cell. If it was passed through the cell
it would have been oxidized to give its GSSG disulfide.48 The disulfide was instead
oxidized by NAPQI, and not by electrochemical oxidation.
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Figure 2.10 Cyclic voltammetry, catalytic oxidation of GSH to GSSG and subsequent
reduction of NAPQI to APAP.82

It turns out that reactive metabolites are not usually produced in large quantities;
however their binding to macro cellular molecules has large impact in ADRs. These
results clearly show that in addition to the GSSG, there is formation of APAP-GSH,
[M+GSH+H+] adduct shown with m/z 457. Due to the nature of their reactivity and low
concentrations, these electrophilic metabolites are difficult to detect and are often
suppressed during detection of endogenous materials. The LTQ Orbitrap has an
advantage of high resolution and has high mass accuracy detection allowing assessment
of the exact nature of the modification that took place on the parent compound. The
conjugate and disulfide were identified based on their accurate mass data, with deviations
of less than 4 ppm. Due to this high sensitivity; low metabolite concentrations can be
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detected using EC coupled to high resolution MS. Physiological processes are such that,
the reactive metabolites are quickly detoxified; thus they will only be available in very
small quantities and therefore will be difficult to detect.

Scheme 2.1: Reaction scheme for the oxidation of APAP in the presence of GSH.48
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A well-known established electrochemical reaction pathway for oxidation of
APAP is a 2 electron oxidation process that is initiated by the loss of single electron and
proton, resulting in formation of a radical,48,81 as shown in Scheme 2.1 above. This will
be followed by another electron and proton loss to give the reactive NAPQI. In the
presence of thiol-containing molecules such as glutathione or n-acetyl-cysteine, it will
form adducts such as the APAP-GSH adduct appearing at m/z = 457. In vivo, APAP is
metabolized and excreted as the nontoxic conjugates of the phase II glucuronidation
reaction. However, during an overdose it saturates all the detoxification conjugation
pathways and depletes intracellular reduced glutathione (GSH), hence the reactive
metabolites will instead react with cellular proteins binding covalently and irreversibly
(haptenation) resulting in cellular necrosis or subsequent liver-induced injury.
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CHAPTER THREE
Electrochemistry-Coupled to Mass Spectrometry in Oxidation of Methimazole:
3.1 Introduction

Methimazole, an antithyroid drug used in the treatment of hyperthyroidism, has
been associated with idiosyncratic toxicity, characterized by skin reactions, leucopenia,
agranulocytosis, aplastic anemia, hepatitis and cholestasis.85,86 The relationship between
idiosyncratic adverse reactions and reactive metabolites is not well established. There is
circumstantial evidence, however, that reactive metabolites generated during oxidation of
methimazole are involved in the onset of idiosyncratic adverse reactions associated with
MMI.87,88 We set out to investigate formation of any unexpected or reactive
intermediates/ metabolites from MMI. These metabolites are electrophilic in nature, thus
reactive, and have the capacity to bind to nucleophilic cellular macromolecules which can
then elicit an immune response. A range of metabolites have been suggested from
biological oxidation of MMI. MMI metabolism is thought to occur through a P450mediated process resulting in ring scission, with further S-oxidation mediated through
FMO to produce the tandem of sulfenic and sulfinic acids.89 However, some sources
reported that FMO sequentially monooxygenates intact methimazole to produce unstable
methimazole sulfenic and sulfinic acids without ring scission.90
The objective of this study was to use electrochemistry and mass-spectrometry to
mimic oxidative metabolism in order to generate and characterize intermediates and
products using electrospray ionization. Various electrochemical methods using modified
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electrodes to enhance catalytic oxidation of MMI have been developed and used for the
determination of MMI at sub-micromolar detection limits using cyclic voltammetry.91-93
While most of these studies were focusing on detection and determination of MMI using
electrochemical techniques, our study is designed to explore metabolic fate of MMI.
Members of the cytochromes P450 class (CYP450) of enzymes are responsible for the
majority of phase I biotransformations leading to reactive electrophilic intermediates.94
The chemical reactivity of electrophilic metabolites usually prevents their detection in
vivo since, by definition, they are short-lived and likely to undergo one or more structural
modifications to form more stable final products. Electrochemical oxidation of thiol
compounds such MMI is complicated by large anodic over potential and poor
voltammetric signals. In the coulometric cell used in this study, the eluent flows through
the electrodes rather than by the electrodes as in convectional cells. This maximizes the
contact of the electro-active compound in solution with the electrode surface, ensuring
that diffusion and convection controlled process do not limit the electrochemical
oxidation of the compound.95
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3.2 RESULTS AND DISCUSSION
3.2.1 Electrochemical Oxidation in basic medium

Technical limitations with respect to the spectrometer cavity could not allow for a
faster flow rate of more than 10 μL per minute. Figure 3.1 shows the on-line negative
mode ESI spectrum obtained, at 5 μL per minute. The residence time of the substrate in
the oxidation chamber was generally long enough for full oxidation of MMI to its full
oxidation products of the sulfonic acid at 600 mV. The reaction could be slowed down
by running the oxidation in basic environments.
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Figure 3.1: On-line negative mode ESI-MS analysis of methimazole oxidized in
ammonium buffer. MMI was infused at 5 µL/minute. At this low flow rate the substrate
has sufficient residence time in the cell allowing complete oxidation to sulfonic acid.
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This spectrum shows a strong peak of the sulfonic acid at m/z =161.003 and
another for the unoxidized substrate, MMI at m/z = 113.01. In-between, there are smaller
peaks at m/z = 129.01 and 145.01. These ramp to the sulfonic acid, m/z = 161.003 by
jumps of 16 amu’s signifying these are putative the sulfenic (or S-oxide) and sulfinic
acids (the dioxide). The relative abundances of the peaks indicate that the sulfenic and
sulfinic acid derivatives are relatively unstable. The rate determining step for the
oxidation of MMI is the formation of the S-oxide.

(a) Methimazole S-oxide

(b) Methimazole Sulfinic Acid

(c) Dimer

Figure 3.2: Putative metabolites from oxidation of MMI
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Subsequent oxidation (after the first 2-electron oxidation) of the S-oxide is facile,
hence the relative low abundance of these metabolites. Structures of the S-oxide and
sulfinic acid metabolites are shown in Figures 3.2 a and b, respectively.
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Figure 3.3: Positive mode. On-line ESI spectrum acquired in basic medium. This
spectrum shows strong peaks for the dimer (m/z = 114.025, not labeled), the sulfenic
acid, and the sulfonic acid. The sulfinic acid is not observed under these conditions.

Figure 3.3 shows spectra derived from on-line spectra in the positive mode. As
expected, the substrate now shows up at m/z = 115.03. There is, surprisingly, a very
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strong peak for the S-oxide at 129.01. There is virtually no evidence for the sulfinic
acid. The major metabolite, before full oxidation to the sulfonic acid, is the doubly
charged dimer, at m/z = 114.025 (Figure 3.2c). A slow oxidation rate will allow the
electrophilic S-oxide to react with the thiol substrate in a condensation-type reaction to
produce the dimer. Dimeric disulfides are not as reactive as the original thiols, and thus
they accumulate. Their further oxidation rates back through the sulfenic acid are
relatively slower.
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Figure 3.4. Negative mode. Off-line synthesis and analysis of MMI oxidation products.
The products were identified with a mass accuracy of 3.93 ppm and 3.43 ppm, absolute
values, for the methimazole sulfinic acid and Methimazole sulfonic acid respectively.
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Figure 3.4 shows the batch off-line experimental spectra. Incubation period was
long enough for the near-full completion of the reaction. Since this is a batch
environment, with no outflow of unreacted metabolites, facile reactions were able to react
to completion. In contrast, negligible amounts of S-oxide are observed; the major
metabolite is the dioxide, methimazole sulfinic acid. Since the batch environment is
constantly in an oxidizing environment, the highly labile sulfenic acid is not observed.
3.2.2 Electrochemical oxidation in acidic media and neutral medium.
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Figure 3.5. Off-line Positive mode. ESI spectrum showing the oxides of Methimazole at
pH 6.75
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The positive mode results of the batch process are shown in Figure 3.5. Basic
environments destabilize electrophilic intermediates. However acidic and slightly acidic
environments stabilize them. Thus, in Figure 3.5, the S-oxide is observed, as well as the
sulfinic acid. The scale excludes the dimer. The Methimazole dimer was the predominant
product in acidic medium Figure 3.8 page 47, structure M4). Figure 3.6 shows strong
peaks for the singly charged dimer at m/z = 227.04 and the doubly charged species at m/z
= 114.03.
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Figure 3.6. Positive mode ESI in acidic medium.
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3.2.3 Choice of supporting electrolyte and effect of pH

Larger currents were attained in phosphate and in ammonium buffers. The same
species obtained at pH 7.4 in phosphate were also obtained in more alkaline media of pH
10.2. Phosphate buffer, however, was not used for subsequent experiments. This was
because phosphate buffers are non-volatile and can clog the MS inlet capillary, hence
ammonium buffer was chosen as the suitable supporting electrolyte in subsequent
experiments.

3.2.4. Assessment of stability, reactivity of metabolites and off-line synthesis

In order to perform off-line synthesis of intermediates, stability of the
electrochemically generated species were monitored over a period of 30 h. To collect
samples off-line, samples were infused at 40 µL/min, with potential maintained at 600
mV. The samples were then collected in vials with one batch kept at room temperature
and the other batch kept at -20oC. Samples were analyzed by ESI-MS. Relative
abundances of the intermediates at m/z 129 and 146 decreased significantly after 26 h. for
both the samples that were kept frozen at -20 oC and those maintained at room
temperature. There was a 75 % decrease in abundance of these intermediates over this
time duration. In addition, stability of MMI was also monitored and was found to be
stable for prolonged periods in solution.
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S-oxidation reactions in vitro had revealed that reactive intermediates are
produced during oxidation of MMI and these can be eliminated by addition of
nucleophiles such as glutathione to the reaction mixture.89 In order to check reactivity of
the intermediate species, samples were also incubated with a select set of nucleophiles.
Conjugates were observed when the samples were incubated with N-acetylcysteine.
Methoxylamine and glutathione, however did not form conjugates with MMI metabolites.

3.2.5 Experimental results derived from nucleophilic trapping.

Figure 3.7 shows the ESI spectrum derived from the use of N-acetylcysteine
(NAC) as the trap. One strong peak is observed, of a 1:1 adduct of NAC with MMI. The
experimental setup involved flowing NAC through a T-junction into the flow going into
the spectrometer cavity (see Figure 2.4 schematic diagram)
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Figure 3.7 MMI metabolite conjugate with N-acetyl cysteine. There is one dominant
adduct 1:1 adduct of the N-acetylcysteine and MMI. There is a small peak for the Soxide and an even smaller peak for the dioxide.

NAC was not electrochemically oxidized. It combined with the effluent from the
electrochemical cell as a reducing thiol. It reacts strongly with any electrophilic species
from the electrochemical cell. The absence of symmetric disulfides is important: it
means no radicals are involved in this mechanism. The only electrophile present in the
electrochemical oxidation cell is the S-oxide. The decrease in abundance of metabolite
and formation of the conjugate strongly indicates that it is the reactive metabolite. The
sulfinic and sulfonic acids are not strong electrophiles. Figure 3.7 thus shows that the
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sulfenic acid is very stable in the oxidizing environment but is quickly and quantitatively
deactivated in a reducing environment such as in the presence of NAC. This (reducing
environment) is the expected medium in the physiological environment. The maintenance
of an oxidizing environment in the electrochemical environment has allowed for the
observation of those highly electrophilic intermediates that would otherwise have been
quenched by the reducing physiological environment
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List of structures

Methimazole (1-methyl3H-imidazole-2-thione)
(S1)

1-methyl-1Himidazole-2-thiol
(S2)

Methimazole S-oxide ( M1)

bis(1-methylimidazol-2yl)disulfide (M4)

1-methyl-2(methylthio)-2,3dihydro-1H-imidazole
(M7)

1-methyl-2,3-dihydro-1Himidazole-2-thiolate (S3)

3-methylimidazolidine3-methyl-2-thioxoimidazolidin2,4-dione ( M3)
4-one (M2)

1-methyl-1H-imidazole-2-sulfinate
(M5)

1-methyl-2,3-dihydro-1HImidazole (M8)
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1-methyl-1Himidazole-2sulfonate (M6)

4-methyl-6-oxa-2,4diazabicyclo[3.1.0]
hexa-1(5),2-diene-3-thiol
(M9)

2-mercapto-1methyl1H-imidazole4,5-diol (M10)

Methylthiourea
sulfenic acid
(M12)

N-methylthiourea
(M11)

N-methylthiourea
sulfonic acid
(M13)

Figure 3.8 List of metabolite from MMI Those labeled with a prefix of ‘S’ indicate
different forms of the substrate, methimazole, and those with ‘M’ indicate metabolites,
either observed in this study or in previous studies.
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3.2.6 NMR experiments

Figure 3.9: NMR spectra of the oxidized MMI products, the NMR shows the ring intact.

NMR experiments were carried out on the products/intermediates. However,
stability of such intermediates is dictated by local environment, after lyophilizing and
purifying the products for NMR analysis, there were changes in environment and
morphology, hence no intermediates were be observed. NMR results obtained showed
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mostly substrate see figure 3.8 above, even after oxidation, it is as expected because the
S-OH bond is unstable.
3.2.7 Mechanism.

All the data derived from electrochemical oxidations suggests a very strong case
for a viable S-oxide. This has been, previously, an elusive metabolite. Very strong and
stable peaks have been observed in Figures 3.3 and 3.5. Figure 3.6, though not showing a
strong sulfenic acid peak, does show a peak for the dimer. This dimer is derived from a
sulfenic acid (vide supra).
The oxidation pathway has a direct correlation with the physiological effects of
MMI. The standard accepted oxidation pathway of sulfur-based drugs is through Soxygenation, though the mechanism of this S-oxygenation differs with specific
compounds based on the environment of the sulfur group. All β-amino sulfur compounds
are oxidized in vivo and in vitro to as far as the sulfonic acid without cleavage of the C –
S bond. Thus most biologically active molecules such as cysteine, glutathione, and
cysteamine show this distinct oxidation pathway.96-98 In the presence of excess oxidant,
the stoichiometry of the reaction was found to be strictly 1:3; with formation of the
sulfonic acid and very little detectable sulfate by BaSO4 precipitation:
3Br2 + RSH + 3H2O → RSO3H (Structure M3) + 6H+ + 6Br-

R3.1

Most deleterious effects of bioactive compounds are ascribed to the reactive
metabolites produced during the first pass metabolism99. By nature of the physiological
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environment, such reactive metabolites are never observed. The first set of experiments
carried out to detect possible reactive intermediates of MMI involved its reaction with
aqueous bromine. This is a ‘clean’ and strong oxidant that oxidizes in 2 one-electron
steps to produce only Br- as its reduced product:
Eo/ V = 1.09

½Br2 (aq) + e-  Br-

This affords the determination of the possible metabolites without interference
from the oxidant. A 1:1 mixture of MMI and aqueous bromine imparts a 2-electron
oxidation which should limit oxidation of MMI to the sulfenic acid. If the sulfenic acid is
stable enough, it should be observed in the ESI spectrum. Figure 3.9 shows a spectrum
of a 1:1 mixture of MMI and aqueous bromine. Even though the spectrum shows the
sulfinic and sulfonic acids; the major metabolite is surprisingly, the S-oxide (Figure 3.2a,
Structure M1). In the absence of the reducing physiological environment, this highly
unstable, electrophilic S-oxide can be stabilized. Unstable S-oxides are known to
disproportionate or to form thiosulfinates. They are also expected to react with the
nucleophilic remaining thiol to produce a dimer:
RSOH + RSH → RSSR + H2O

R3.2

Under insufficient oxidant equivalents, the substrate will partition into its most stable
intermediates at those conditions. Spectrum in Figure 3.9 shows that the sulfinic acid, as
expected, is not as stable as the sulfonic acid, which is the final oxidation product. This
spectrum was taken after complete consumption of bromine and before full
rearrangement of the sulfur compounds as evidenced by the coexistence of the S-oxide
and the thiol. The spectrum obtained in Figure 3.9 was derived from unbuffered
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solutions. pH of the reaction solution decreased due to formation of H+ according to the
reaction stoichiometry. Thus the m/z peak at 116.99 can be ascribed to the substrate, and
the 115.03 to the dimer. After long incubation periods the substrate peak disappears
completely, with a concomitant increase in the dimeric species and other unidentifiable
thiosulfinates. The sulfonic and sulfinic acids still show up at the expected m/z values
because of their acidity, and thus unlikely to be further protonated despite the highly
acidic product environment.
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Figure 3.10: ESI spectrum of oxidation of methimazole using bromine in a 1:1 mixture
ratio. As expected, the sulfenic acid is the major metabolite in these conditions of excess
reductant.
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3.2.8 Proposed mechanism for electrochemical oxidation of methimazole

Our experimental results can now allow us to suggest a plausible mechanism of
electrochemical oxidation of MMI. This is shown in Scheme 3.1. Electrochemical
oxidation of sulfur-based drugs is complicated by the fact that sulfur centers generally
oxidize via 2-electron jumps, while electrochemical abstractions generally involve a
single electron transfer at a time. Starting with the thiol center would produce a sulfurbased thiyl-type radical on abstraction of the first electron. This would immediately
precipitate a cascade of free radical reactions with a strong formation of the dimeric
disulfide. Our results thus lead us to the conclusion that the abstraction of the first
electron results in the formation of a positive charge delocalized mostly over the C-N-C
network and not a sulfur-based radical. Zwitterionic forms of thioureido oxo-acids have
similarly been described.100
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Scheme 3.1: Reaction scheme for the oxidation of MMI and subsequent formation of
sulfenic acid

Scheme 3.2 below summarizes different fate of sulfenic acid. Depending on the
environment, the sulfenic acid will react to give stable states. The reaction of sulfenic
acid with nucleophiles such as n-acetyl cysteine may be advantageous in the
physiological environment, as this is a detoxification pathway. Other pathways also leads
to less reactive metabolites.
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Scheme 3.2: Summary of sulfenic acid
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3.2.9 Comparison with biological metabolism

Since MMI is a well-tolerated drug for hyperthyroidism, its in vitro and in vivo
metabolism has been extensively studied. Human, rat and pig microsomal incubations
with MMI have concluded that the major activation of MMI is performed by FMO’s
rather than CYP450’s. Presence of FMO’s however, seemed to deactivate CYP-based
bioactivations, and it has since been established that MMI is a competitive inhibitor of
FMO’s.101,102 Isolation of the effect of CYP450’s can be determined by heating, which
deactivates FMO’s or addition of N-octylamine, which inhibits FMO bioactivations.
The variety of metabolites obtained which involved ring cleavage to obtain methyl
thiourea and its oxo-acids (structures M11 – 13 in Figure 3.8) can be attributed to
CYP450-mediated bioactivations. This can be justified through the initial epoxidation of
MMI (structure M9) whose subsequent hydrolysis product of a 1,2 dihydroxy moiety can
easily cleave the C-C bond by even the mildest oxidants. Thus one expects a wide
variety of possible metabolism products when microsomal oxidations are utilized to
metabolize MMI. The major pathway of microsomal bioactivation of MMI involves Soxygenation, with the sulfinic acid (structure M2) as the major metabolite. While the
sulfenic acid has been postulated (structure M1), microsomal incubations have never
been able to isolate it; even though formation of M2 has to pass through M1. Our study
has been able to isolate this formerly postulated metabolite. The deactivation of
CYP450’s is clearly related to formation of a highly reactive electrophilic metabolite of
MMI derived from FMO’s. This has been observed with the oxidation of a novel kinase
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inhibitor, TG100435.103,104 Its bioactivation by FMO’s gives an S-oxygenated S-oxide,
TG100855, which not only deactivates CYP450’s but is also reduced back to TG100435
during the deactivation. Thus the products, kinetics and dynamics of microsomal
bioactivations are expected to be complex. Our electrochemical oxidations simplify this
process. This makes evaluation of physiological effects, especially toxicities, easier to
determine.
3.4 Conclusion

We have demonstrated that electrochemistry coupled to mass spectrometer can
mimic oxidative metabolism of MMI, the mechanism initiated by single e- transfer
process coupled to proton (H+) abstraction. The absence of complex endogenous
material enhanced detection of an S-oxide in oxidation of MMI, this intermediate
metabolite has been speculated before, but has never been isolated. The elusive sulfenic
acid was captured as a conjugate with n-acetyl cysteine. Bioactivation of MMI and
related molecules, to reactive metabolites has a direct physiological implication in
toxicity of thionamides.
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CHAPTER FOUR
Kinetics and Mechanism of Oxidation of Methimazole by Chlorite in Slightly Acidic
Media
4.1 Introduction

As indicated above, thionamides drugs, methimazole (1-methyl-3H-imidazole)
MMI and 6 -propyl- 2-thiouracil (PTU) are two important antithyroid drugs used in
treatment of hyperthyroidism and thyrotoxicosis.105,106 After administration, the drugs
are concentrated in the thyroid gland.107 Hypochlorous acid (HOCI) is the most powerful
oxidant produced by human neutrophils. Peroxidases including thyroid peroxidase have
been shown to contribute to oxidation of MMI, to a range of products.108 Model in vitro
studies, using myeloperoxidase (MPO) in H2O2/Cl- system, show that hypohalous acids
are some of potent oxidants generated during catalytic oxidation of H2O2 in presence of
Cl- or Br-.109 Ironically MMI is an antioxidant that scavenges reactive species, and can
be oxidized to potentially reactive intermediates, such as its sulfenic acid.
A number of toxicological and metabolic studies have been conducted in an
attempt to identify possible reactive intermediates associated with the antithyroid
drugs.110 Whereas there is a general consensus on the ultimate products of oxidation of
MMI, as sulfate and N –methyl-imidazole,111 there has not been a clear identification of
possible intermediates. Other metabolites suggested from previous research include Smethyl imidazole, 1 methyl-2-thiohydantoic acid, methylhadantoin and
methylthiourea.112 However, lack of toxic profiles by most of these metabolites could not
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explain the trend in observed adverse reactions associated with MMI. Here a system that
employs potent oxidants hypohalous acids; HClO and HBrO which were generated in
situ were used to study the rapid kinetics and mechanism of reaction of MMI oxidation.
With mild oxidants such as bromine, a stable S-oxide was observed. However, in
acidified chlorite the reaction was very fast and the resulting in the unstable intermediate
that was short lived and was not observed in ESI.
4.2 Results and discussion

2.0

Absorbance

1.5

(c)
1.0

0.5

(a)

(b)
0.0
200

300

400

500

600

700

wavelegnth (nm)
-5
-4
-4
Figure 4.1. Spectral
(a)ClO2
[MMI]
1.00
M, (b) ClO2 = 1.70 x10-4 M
(a) [MMI] scans
= 1.0 Xshowing
10-5 M, (b)
1.7-4=
X 10
MX10
-and product of-3reaction [MMI] = 3.0 x 10 M
-3 2 ] = 3.00x- 10
-1
and (c) product of reaction [MMI] =[ClO2]
3.00 =x 3.0
10 x, 10
[ClO
and
[HClO
]
=
4
M and [HClO 4] = 1.0 x10 M
1.00 X 10-1 M

58

4.2.1 Stoichiometry.

Stoichiometric determinations utilized two complementary techniques:
spectrophotometric and titrimetric. The titrimetric techniques were more accurate as they
relied on a several readings to derive a single stoichiometry. Figure 4.2 shows a
titrimetric analysis of residual oxidizing power. For the whole data set shown, MMI
concentrations were fixed at 1.00 mM. Iodometric titrations gave the expected linear plot
which extrapolated to 2.0 mM chlorite concentrations, showing complete consumption of
1.0 mM MMI. Each chlorite molecule gains 4 electrons to attain the Cl- state. This
suggests that the only oxidation on the MMI molecule occurs on the sulfur center which
is oxidized from -2 to +6. Tests with barium chloride showed an almost quantitative
formation of sulfate as expected from MMI.
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Iodometric Titration to Determine the Stoichiometric Ratio
between MMI and Chlorite
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Figure 4.2. Iodometric titration to determine stoichiometry. Fixed [MMI] = 1.00 x10-3 M
, [H+] = 0.20 M, and varied [ClO-2] from 3.00 x 10-3 M to 8.00 x10-3 M, X intercept =
0.002033 This suggests an oxidant to reductant stoichiometric ratio of 2:1
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Despite the observed clean 2:1 stoichiometry, we could not experimentally
determine the organic residue. However, the residue did not seem to involve any further
oxidation, only hydrolysis and/or ring-opening. ESI spectra of the reaction were
acquired in solution using slightly less than stoichiometric amounts of oxidant. Figure 4.3
shows an ESI spectrum in the positive mode. It shows, predominantly, the dimeric
species at m/z = 227.04313 and the N-methylimidazole at m/z = 83.0604. Nmethylimidazole would be the expected organic residue if the sulfur atom is oxidized to
sulfate with a concomitant cleavage of the C-S bond. It would appear N-methylimidazole
rapidly decomposes by hydrolysis to smaller fragments after ring opening.
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Figure 4.3: ESI spectrum in the positive mode before reaction proceeds to completion
showing the predominant peak of the substrate at m/z = 115.03242. Two peaks for the
dimeric species are observed, one at m/z = 227.04313. The doubly-charged dimeric
species is observed as the peak just below that of the substrate. The N-methylimidazole
species is at m/z = 83.06402.
Figure 4.4 shows the ESI spectrum of chlorite and MMI with slightly less chlorite
than that needed for full oxidation of MMI. As expected, there is a predominant peak for
sulfate, captured as the bisulfate at m/z = 96.96032. There is a large peak for the sulfonic
acid of MMI at m/z = 161.00252. A further 2-electron oxidation of this sulfonic acid will
give sulfate and N-methylimidazole. There is a very tiny peak for the sulfenic acid at
129.01273, but, surprisingly, there is no sulfinic acid, which is supposed to be more
stable than the sulfenic acid. Another stoichiometric determination was attempted for
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the chlorine dioxide – methimazole reaction. From the radical nature of chlorine dioxide,
the stoichiometry could not be determined with certainty. From electron balance alone,
we were expecting an 8:5 ratio, oxidant to reductant, but this was never obtained. We
can, however, write the following general equation for the oxidation of MMI by chlorite:
MMI + 2ClO2- + 2H2O → MMI-Oxidation products + 2 Cl- + SO42- + 4H+ (R4.1)
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Figure 4.4: ESI spectrum in the negative mode. Sulfate is the dominant product, as
expected, at m/z = 96.96032. The sulfonic acid can be seen at m/z = 161.00252. The
substrate can still be seen at 113.01798.
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4.3 Reaction Kinetics.

Figure 4.5 shows rapid kinetics scans of the reaction mixture which shows
activity at 260 nm and 360 nm. The peak at 260 is consistently decreasing peak at 260,
This peak which is attributed to λmax for methimazole, Figure 4.1 trace (a). Another peak
of importance is at 360 nm, it commences after an induction period determined by initial
conditions. This peak is attributed to ClO2 . The peak at 260 nm is at its lowest when that
at 360 nm reaches its peak. Chlorine dioxide color slowly faded after prolonged standing
due to its decomposition and volatility. In high acid conditions, the absorbance
measured at 360 nm attained a transient peak which then slowly decreases to its final
value, hinting some olligooscillatory behavior.
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Multiple scans of Methimazole oxidation by chlorite in aqueous acidic medium
at 60 seconds interval
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Figure 4.5: Multiple scan of MMI oxidation by chlorite in aqueous acidic medium at 60
-4
seconds intervals.
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Figure 4.6 shows the effect of MMI on the chlorite-MMI reaction. Chlorine
dioxide formation commences almost immediately after mixing. In all traces shown in
this figure, chlorite was in stoichiometric excess over MMI, that is; the ratio was over
2:1. The transient peak in chlorine dioxide absorbance is attained within 2 seconds. If
this reaction is monitored further, the chlorine dioxide will attain a minimum value which
remains invariant for up to an hour. The final chlorine dioxide concentration is
determined by the excess chlorite concentrations. This effectively involves the wellknown disproportionation of chlorite in acidic environments.113
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5ClO2- + 4H+

→ 4ClO2(aq) + Cl- + 2H2O

(R4.2)
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Figure 4.6. Variation of [MMI] o and its oxidation , Fixed [ClO2-] = 2.50 x10-3 M, [H+]
= 5.00 x10-2 and varied [MMI] (a) 5.00 x 10-4 M, (b) 6.00 x 10-4 M, (c) 7.00 x 10-4 M, (d)
8.00 x10-4 M (e) 1.00 x10-1 M and (f ) 1.10 x 10 -3 M
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Variation of Chlorite
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Figure 4.7. Effect of [ClO2-] o variation on the reaction with MMI. Fixed:[MMI] = 1.00
x10 -3 M, [H+] = 0.01 M and varied [ClO2-] = (a) 1.00 x 10-2 M, (b) 2.00 x 10-2 M, (c)
4.00 x10-2 M, (d) 6.00 x 10 -2 M and (e) 1.00 x10 -1 M. INaClO4 = 1.00 M.

Figure 4.7 shows the variation of initial chlorite concentrations at a pH of 1.00.
The reaction is much faster than those reactions run at pH 1.3 in Figure 4.6, above, and
the transient peak of chlorine dioxide is attained much earlier. The peak is also much
sharper. Figure 4.8 shows the complex dependence of the reaction on acid
concentrations. Lower concentrations gave a monotonic increase in chlorine dioxide
concentrations within the 5 seconds observation window. Higher acid concentrations
gave oligooscillations. Acid catalyzed a faster initial rate of formation of chlorine
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dioxide. Absorbance traces, for the range of acid concentrations studied, seemed to all
converge at a specific absorbance value 1.3 seconds into the reaction. It was not possible
to determine the significance of this coherence since this could not be related to an
isosbestic point: nothing else absorbs at 360 nm apart from chlorine dioxide. Thus it
could merely be a saturation point.

Variation of acid
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Fixed [MMI] = 0.0008, [ClO2-] = 0.0025, Varied [H+] = (a) 0.0025 (b) 0.005 (c) 0.01
(d) 0 0.03 M, (e) 0.05

Figure 4.8. Effect of [H+] o variation on the reaction with MMI with ClO2-. Fixed:
[MMI] = 1.00 x10-3 M, [ClO2-] = 2.50 x10-3 M, varied [H+] = (a) 2.50 x10-3 M (b) 5.00
x 10-3 M, (c) 1.00 x10-2 M, (d) 3.00 x10-2 (e) 5.00 x10-2 M and 0.01 M. INaClO4 = 1.00 M.
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4.3.1 Chlorine dioxide-MMI reaction kinetics

The direct reaction of chlorine dioxide with MMI was also studied. With the
observed oligooscillations in chlorine dioxide concentrations, it meant this reaction was
directly relevant. It appears the reactions that form and consume chlorine dioxide are
approximately of the same order of magnitude in rates, with the dominance of each being
determined by the presence of the relevant reagents. If the chlorine dioxide – MMI
reaction was much faster than the chlorite – MMI reaction, then one would observe an
induction period followed by formation of chlorine dioxide, and in the opposite case, one
would observe a monotonic increase in chlorine dioxide formation up to its final
absorbance. However, what we see here is non-linear behavior. Figure 4.9 shows the
effect of varying chlorine dioxide concentrations. Of note, traces, a to e, apart from trace
f, all contain stoichiometric excess of MMI such that, at the end of the reaction, all
chlorine dioxide would have been expended. The observed residual absorbance of 0.02
units is derived from the other products in the reaction mixture. Thus the reaction will
appear to be rapidly shutting down due to contribution to the absorbance from the
product.
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The direct reaction of chlorine dioxide and MMI appears to be very rapid in this
unbuffered environment; essentially over in 200 msec. Our stopped-flow instrument has
a mixing time of 1.0 msec, and from the experimental traces observed in Figure 4.9, it
appears the first electron transfer is too rapid to be observed. For example, for trace f, we
expect an initial absorbance of 0.110, and our observed initial absorbance is 0.088. Thus
the initial step of this reaction will involve a rapid adduct formation between the radical
chlorine dioxide and the nucleophilic sulfur center of MMI, as shown below.
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Scheme 4.1 Proposed MMI-Chlorite adduct formation and concomitant formation of
sulfenic acid
Figure 4.10 shows the variation of MMI concentrations. MMI is in stoichiometric
excess in all these traces. There is, progressively a decrease in observed initial
absorbance of chlorine dioxide as initial MMI concentrations are increased, indicating the
presence of an initial rapid step which is beyond the capabilities of our stopped-flow
spectrophotometer.
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Variation of MMI on reduction of ClO2
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Fixed ClO2, = 5.0 x 10-5 M and varied [MMI]= 2.5 x10-5 M , (b) 2.6 x 10 -5 M, (c) 2.7 X 10-5 M

Figure 4.10:
Variation of [MMI] o and their effect on rate of reaction, Fixed [ClO2] =
-5 (d) 2.8 x 10 -5 M, (e) 2.9 x 10-5 M, 5.0 x -510-5
5.00 x10 M, and varied [MMI] (a) 2.50 x 10 M, (b)2.60 x 10-5 M, (c)2.70 x 10-5 M, (d)
2.80 x10-5 M (e) 2.90 x10-5 M (f ) 5.00 x 10 -5 M

Thus it becomes very difficult to determine an initial rate of reaction, except a
lower limit rate constant with no statistical analysis nor error bars. Both Figures 4.9 and
4.10 suggest bimolecular kinetics with the reaction first order in both chlorine dioxide
and MMI.
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4.3.2 Chlorite-MMI reactions at λmax 260 nm.

Absorbance traces at 360 nm show formation of chlorine dioxide due to the MMI
– Chlorite reaction. Spectral scans in Figure 4.1 show an initially isolated peak for MMI
at 260 nm. Absorbance observations at this wavelength could show us the initial
dependence of the reaction on MMI and chlorite, as well as the requisite initial rate. We
had initially evaluated an absorptivity of MMI at 260 nm of 11412 M-1 s-1. Figure 4.11
shows the dependence of MMI on the MMI – Chlorite reaction. The reaction was run at
0.25 M acid, and was over in about 2 s. It was first order in MMI.
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Figure 4.11: Effect of [MMI] o variation on its oxidation by chlorite at 260 nm. [ClO-2,]
=2.50 x 10-3 M, [H+] = 0.25 M and varied [MMI] = (a) 1.40 x 10-4 M, (b) 1.30 x 10 -4
M, (c) 1.20 x 10 -4 M, (d) 1.10 x10-4 M, (e) 1.00 x10 -4 M

Figure 4.12 shows absorbance traces taken at 260 nm while varying chlorine
dioxide. These plots are significant: With MMI maintained at a constant initial
concentration, one notices that the starting absorbance readings are invariant over the
series of experiments undertaken. This implies that our stopped-flow instrument is able
to capture the whole reaction sequence, i.e. there is not initial rapid section of the reaction
that is not within the mixing time limitations of the instrument.
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Figure 4.12: Effect of varying [ClO2-] o on oxidation of MMI at 260 nm Fixed [MMI,]
=1.2 x 10-4 M, [H+] = 0.25 M and varied [ClO2-] = (a) 1.0 x 10-3 M, (b) 1.5 x 10 -3,
(c) 1.8 x 10 -3, (d) 2 x10-3 M, (e) 2.5. x10-3 M (f) 3.0 x10-3 M

Although chlorite was in overwhelming excess over MMI, no pseudo-first-order kinetics
are observed. This is as a result of the residual absorbance derived from the products.
Both Figures 4.11 and 4.12 delivered a bimolecular rate constant for the MMI – chlorite
reaction of 3.02 ± 0.42 x 102 M-1 s-1.
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Figure 4.13: Effect of acid variation on oxidation of MMI. Fixed [MMI,] =1.30 x 10-4
M, [ClO2-] = 0.25 M and varied [H+] = (a) 0.10 M, (b) 0.20 M, (c) 0.30 M, (d)0.40
M, (e) 0.50 M
Figure 4.13 shows the acid dependence of the reaction. Acid seems to have very little
effect on the reaction. Higher acid concentrations marginally increase the rate of
reaction, however, it gives a higher residual absorbance at the end of the reaction.
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4.4 Mechanism

The almost instantaneous formation of chlorine dioxide implies that there is a
rapid formation of HOCl in the initial phase of the reaction. Hypochlorous acid is known
to rapidly react with chlorite in acidic medium to form chlorine dioxide114:
2ClO2- + HOCl + H+ → 2ClO2(aq) + Cl- + H2O

R4.3

Thus it would appear that the initial oxidation/reduction involved 2-electrons to produce
HOCl and the oxidized form of methimazole, the sulfenic acid. Assuming that
methimazole can be represented as RSH, the enol form; the sulfenic acid can be
represented as RSOH as represented in the

Scheme 4.2: The keto and enol forms of MMI

Scheme 4. 3: The initial oxidation scheme of MMI to form the sulfenic and S-oxide
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RSH + ClO2- + H+ → RSOH + HOCl

R4.4

The sulfenic acid is known to be unstable and can either be further oxidized to the
sulfinic acid in excess oxidant, or to the dimeric species in excess reductant.
RSOH + [O] → RSO2H

R4.5

2RSOH → RSSR + H2O

R4.6

This has been confirmed by an experiment in which MMI is reacted with one equivalent
of aqueous bromine.62 This will impart a 2-electron oxidation on MMI. This should halt
the oxidation at the sulfenic acid if the sulfenic acid is stable. If the sulfenic acid is not
stable, we would expect a series of sulfur oxo-acids. This has been thoroughly described
in section 3.2.7.
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4.4.1 Oxychlorine chemistry:
Chlorine dioxide formation is so rapid. Its formation is enhanced by the
formation of a reactive species, HOCl. There is however another intermediate species
involved in the sequence. This was identified as the asymmetric intermediate Cl2O2
speciesc.115,116
ClO2- + HOCl + H+ ⇄ Cl2O2 + H2O

R4.7

Cl2O2 + 2H+ + 2e- ⇄ 2HOCl

R4.8

Addition of R4.7 and R4.8 gives quadratic autocatalysis in HOCl in excess ClO2-.
ClO2- + HOCl + 3H+ + 2e- → 2HOCl + H2O

R4.9

Formation of HOCl thus exponentially increases the formation of more HOCl. One can
assume, then, that the major oxidizing species in the reaction medium is HOCl:
HOCl + RSH → RSOH + Cl- + H+

R4.10

HOCl + RSOH → RSO2H + Cl- + H+

R4.11

HOCl + RSO2H → RSO3H + Cl- + H+

R4.12

HOCl + RSO3H + H2O → N-Methylimidazole + SO42- + Cl- + 3H+
R4.14
As Cl- builds up, the hydrolysis reaction of Cl2 becomes relevant:
HOCl + Cl- + H+ ⇄ Cl2 + H2O
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R4.15

The lack of gaseous chlorine observation indicates that the Cl2 – MMI is very rapid.
4.4.2 Effect of chloride:

There has been some debate in oxychlorine kinetics on the reaction of chlorite and
chloride:117,118
ClO2- + Cl- + 2H+ → 2HOCl

R4.16

Effect of varying choride
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M, [H+] = 2.5 x 10-3 M, [ClO2-] = 2.5 x 10-3 and (a) No Cl- , (b) [Cl-] = 1.0 x10-3 M (c)
2.0 x10-3 M, (d) 3.0 x10-3 M, (e) 5.0 x 10-3 M. There is minimal effect of chloride on the
overall reaction.
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It is clear from above experiment that, there is minimal effect of chloride on the overall
reaction.
There is a very viable and well-known analogue of reaction R4.16 involving bromous
acid:
HBrO2 + Br- + H+ → 2HOBr

R4.17

Equilibrium of reaction R4.17 lies more to the right, with formation of HOBr enhancing
the rate of reaction since, in all bromate oxidations, HOBr is the major oxidizing species.
Thus bromate oxidations are catalyzed by addition of bromide. Figure 4.14, however,
shows that chlorite has little effect on the reaction, thus conforming that Reaction R18 is
essentially inert.

4.4.3 Effect of acid:

Both chlorite – MMI and chlorine dioxide – MMI reactions show complex
dependence on acid. This is due to effectively two acid-base equilibria that are relevant
in the reaction mixture. The first is the dissociation constant of chlorous acid:
ClO2- + H+ ⇄

HClO2;

Ka-1

R4.18

And the second involves protonation of the thiol center:
RSH + H+ ⇄ RSH2+;

Kb
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R4.19

The protonation can also occur with the keto-form of MMI in which the 5-membered
imidazole ring can be represented as R1R2:
R1R2C=S + H+ ⇄ [R1R2C=S-H]+

R4.20

The ideal situation for the fastest initiation, reaction R4.4-type reaction would involve the
protonated thiol with the unprotonated Cl(III) species:
ClO2- + RSH2+ → HOCl + RSOH

R4.21

Reaction R4.21, however, is an unlikely combination, given that pKa of chlorous acid is
1.72. Low pH conditions will have negligible concentrations of ClO2- and high pH
conditions will have negligible concentrations of protonated MMI. Thus from the
combination of reaction R4 with equilibria R4.18 and R4.19:
HClO2 + RSH → RSOH + HOCl

R4.20

HClO2 + RSH2+ → RSOH + HOCl + H+

R4.21

The experimentally observed acid dependence can be explained as following. At pH
conditions less than 1.0; virtually all Cl(III) species will be in HClO2. The thiol
protonation scheme is very rapid in either direction. Thus there is only minimal acid
catalysis in the chlorite – MMI reaction between pH 1.0 and 0.301; as is shown in Figure
4.12. However, all oxychlorine reactions proceed faster with acid, especially the
composite reaction for the formation of chlorine dioxide, reaction R4.3. Thus, at the
initial part of the reaction, high acid would catalyze formation of chlorine dioxide. After
the initiation reaction(s) that form HOCl, the HOCl can proceed to oxidize MMI and its
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sulfur oxo-acids, R4.10 to R4.11, or proceed to oxidize chlorite to chlorine dioxide.
Kinetics data suggests that these two sets of reactions, those that form and consume
HOCl are of approximately equal magnitude, hence the oligooscillatory behavior
observed in chlorine dioxide formation. Acid will catalyze formation of HOCl much
more rapidly than the oxidation of MMI by HOCl. HOCl, being an electrophile, reacts
faster with the unprotonated thiol.

4.4.4 Reaction of chlorine dioxide and MMI.

The direct reaction of chlorine dioxide is initially slower than reactions that
produce chlorine dioxide; hence there is the immediate and almost instantaneous
production of chlorine dioxide in the chlorite – MMI reaction. Acid has a minimal effect
on this reaction. Bimolecular kinetics suggest the first step of the reaction is an initial
adduct formation between chlorine dioxide and MMI. Chlorine dioxide is a radical
species, and the first step is the addition of an electron to the odd-electron deficient
chlorine center to a more stable species; the Cl(III) chlorite:
ClO2 + e- → ClO2- ; E0 = 0.94 V

R4.22

Chlorite will then continue with the oxidation of the substrate.
R1R2C=S + ClO2 ⇄ [R1R2C=S-ClO2]
[R1R2C=S-ClO2] + ClO2 + H2O → R1R2C-SOH + 2ClO2- + 2H+
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R4.23
R4.24

This reaction is solvent assisted; with the reaction faster in protic solvents and sluggish in
solvents such as acetonitrile.119 Thus for bimolecular kinetics to prevail, the solvent
dissociates the adduct in reaction R4.24 first before addition of the second chlorine
dioxide molecule. If the order was reversed, third order kinetics would have been
observed. The adduct will have a partial positive charge, which can be attacked by a
nucleophile. This would give an unstable Cl(II) intermediate which can rapidly react, in
a non-rate-determining manner, with chlorine dioxide, to form chlorite.
[R1R2C=S-ClO2] + H2O ⇄ [R1R2C=SOH]+ + HClO2- ; rds

R4.25

HClO2- + ClO2 → 2ClO2- + H+

R4.26

The [R1R2C=SOH]+ intermediate can lose a proton to give an S-oxide or a sulfenic acid.

4.4.5 Oligooscillations

Figures 4.6 and 4.7 all show that chlorine dioxide attains a transient maximum
before decaying to its final value. Rate of chlorine dioxide production is dependent on
the rate of formation of HOCl since subsequent formation of chlorine dioxide is
autocatalytic in HOCl. Figure 4.7 reflects this logic. Higher acid concentrations display
a higher rate of formation of chlorine dioxide. Lower acid concentrations display a lower
chlorine dioxide production rate such that the concentrations of chlorine dioxide do not
‘over-shoot’ its expected stoichiometric concentration and a monotonic rate of formation
is observed as in trace (a) in Figure 4.7. Figure 4.6 echoes the same logic. Lower chlorite
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concentrations display a monotonic rate of chlorine dioxide formation (trace (a) in Figure
4.6) due to the lower rate of formation of HOCl and subsequently chlorine dioxide.
4.5. Overall reaction scheme.

Table 5.1 shows the full set of reactions involved in this reaction mixture. There
are three oxidizing species in the reaction mixture: Cl(III), ClO2 and HOCl. There are 4
possible reducing species: MMI, the sulfenic, sulfinic and sulfonic acids, sulfite and
Cl(III). Chlorite, Cl(III), whether in the protonated or unprotonated forms, acts as either
an oxidizing agent (for the substrate), or a reductant (for HOCl to form chlorine dioxide).
Table 5.1 encompasses all three possible reactions: ClO2- - MMI; ClO2 – MMI and ClO2- HOCl reactions. The table assumes all oxidation reactions, except those involving
purely only oxychlorine species among themselves, are irreversible. Most of the kinetics
of the oxychlorine species are well known. Those involving MMI oxidations were
estimated in this study. The initiation reactions that produce the reactive species HOCl
are represented by reactions M4 to M6. The highly unlikely combination of unprotonated
ClO2- and the protonated MMI was not included in this scheme. The autocatalysis
involves reaction M7 in combination with any of reactions M9, M10 and M11. With
establishment of HOCl as the autocatalytic species, after the initiation reactions, one can
use HOCl as the sole oxidizing species with very little loss in accuracy. This implies
addition of reactions M17 to M21 does not improve the model except when there is
overwhelming excess of chlorite. Oxidation of the sulfonic acid could be through the
entropy-driven composite reaction M19, or through the 2-step process M22 and M23.
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HSO3- is labile and easily oxidized to sulfate even by the mildest oxidizing agents; thus
just the use of reaction M17. Chlorine dioxide reactions are represented by reactions
M24 to M28. The activities of aqueous chlorine dioxide, at various low pH conditions,
however, were not known. Some of the wavy traces observed, e.g. Figure 4.6 and 4.7
were derived from formation of gaseous ClO2. This precluded a successful modeling of
the reaction scheme.
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Table 4.1. Chlorite – Chlorine Dioxide – MMI reaction.
No.

Reaction

M1

ClO2 + H+ ⇄ HClO2

M3

R1R2C=S + H+ → [R1R2C=S-H]+

M4

ClO2- + R1R2C=S + H+ → R1'R2CSOH + HOCl

M5

HClO2 + R1R2C=S → R1'R2CSOH + HOCl

M6

HClO2 + [R1R2C=S-H]+ → R1'R2CSOH + HOCl + H+

M7

ClO2- + HOCl + H+ ⇄ Cl2O2 + H2O

M8

Cl2O2 + ClO2- ⇄ 2ClO2(aq) + Cl-

M9

Cl2O2 + R1R2C=S + H2O → R1'R2CSOH + 2HOCl

M10

Cl2O2 + R1'R2CSOH + H2O → R1'R2CSO2H + 2HOCl

M11

Cl2O2 + R1'R2CSO2H + H2O → R1'R2CSO3H + 2HOCl

M12

Cl2O2 + R1'R2CSO3H + H2O → R1R2C=O + SO42- + 2HOCl + 2H+

M13

HOCl + R1R2C=S → R1'R2CSOH + H+ + Cl-

M14

HOCl + R1'R2CSOH → R1'R2CSO2H + H+ + Cl-

M15

HOCl + R1'R2CSO2H → R1'R2CSO3H + H+ + Cl-

M16

HOCl + R1'R2CSO3H + H2O → R1R2C=O + SO42- + 3H+ + Cl-

M17

ClO2- + R1'R2CSOH + H+ → R1'R2CSO2H + OCl-

M18

ClO2- + R1'R2CSO2H → R1'R2CSO3H + OCl-

M19

ClO2- + R1'R2CSO3H + H2O → R1R2C=O + SO42- + OCl- + 2H+

M20

HClO2 + R1'R2CSOH → R1'R2CSO2H + HOCl

M21

HClO2 + R1'R2CSO2H → R1'R2CSO3H + HOCl

M22

R1'R2CSO3H + H2O → R1R2C=O + HSO3- + H+

M23

HSO3- + HOCl → SO42- + 2H+ + Cl-

M24

ClO2(aq) + R1R2C=S ⇄ [R1R2C=S:ClO2]

M25

[R1R2C=S:ClO2] + ClO2(aq) + H2O  R1'R2CSOH + 2H+ + 2ClO2-

M26

ClO2(aq) + R1'R2CSO2H ⇄ [R1'R2CSO2H:ClO2]

M27

[R1'R2CSO2H:ClO2] + ClO2(aq) ⇄ R1'R2CSO3H + 2H+ + 2ClO2-

M28

ClO2 + HSO3- ⇄ [O2ClSO3H-]

M29

2 R1'R2CSOH ⇄ R1'R2CSO2H + R1R2C=S

-
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4.6. Conclusion

MMI is oxidized by chlorite and chlorine dioxide all the way through to
desulfurization. Chlorite oxidation of MMI produces negligible amounts of the S-oxide
(see Figure 4.4) and no evidence of the sulfinic acid. The sulfonic acid is a major
pathway of oxidation before formation of sulfate and N-methylimidazole. The lack of
observation of substantial amounts of the sulfenic and sulfinic acids in the ESI spectrum
does not preclude their presence in the pathway and mechanism: it just means that these
oxoacids are very unstable and are easily oxidized further.

88

CHAPTER FIVE
Electrochemical and Enzymatic in Vitro Studies, of 6-propyl-2-thiouracil
5.1. Introduction

6-propyl-2- thiouracil (PTU) is an antithyroid drug that was introduced close to
seventy years ago.86 This drug is effective in the treatment and management of Grave’s
disease, an autoimmune diseases mediated by thyroid stimulating immunoglobulins;
resulting in hyperthyroidism, which is over production of thyroid hormones.120 It works
by inhibiting the activity of thyroid peroxidase and blocks the conversion of thyroxine
(T4) to triidothyronine (T3). The action of PTU may partly depend on its ability to
function as a thiol as shown by tautomer forms below.121

Figure 5.1 Tautomers of PTU
Although effective, PTU has been associated with rare but severe idiosyncratic
toxicity, characterized by; skin reactions, agranulocytosis, aplastic anemia, hepatitis and
cholestasis. 85,86 PTU is identified as being the third most frequent cause of drug-induced
liver transplant in the United States.122 In 2008, a panel of experts extensively reviewed
adverse events reports and case reports of PTU-induced liver failure and deaths. They
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recommended that PTU should not be used as first line of therapy in Grave’s disease.123
In 2010 the Food and Drug Administration (FDA) issued a black box warning about
severe liver injury associated with treatment using PTU. Hepatotoxicity of therapeutic
drugs is not a new phenomenon in drug therapy.
A number of drugs have already been withdrawn from market after cases of
severe toxicity where noted. Bioactivation of drugs resulting in reactive metabolites is
considered as the initial step towards drug induced organ damage.124 Presumably the
hepatotoxicity associated with PTU is due to its reactive metabolites in the liver, these
could be radicals or electrophiles. However, as of now, there are no reports on the PTU
reactive metabolite(s) formation in liver, and the role of the formed intermediates in the
hepatotoxicity induced by this drug is ambiguous.125 There has been a variety of
metabolites observed from PTU metabolism. Two oxidation systems were examined for
the oxidation of PTU. Metabolites generated by electrochemical oxidation were
compared to those that were identified from microsomal oxidation. Slight differences
were noted in the identity of the metabolites.
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5.2 Results and discussion
5.2.1 Electrochemical oxidation of PTU in basic medium

Electrochemical oxidation of PTU was carried out using the arrangement shown in figure
2.4. Initial experiments were carried out in the absence of trapping agents. Control
experiments were initiated with the cell turned off at 0 potential. Figure 5.2 clearly
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Figure 5.2 ESI (-) MS, with cell turned off 0 mv obtained for 0.1 mM PTU in ammonium
in 20 mM ammonia, 20% MeOH, pH 10, Flow rate 10 µL/min.

shows a clean ESI-spectrum of PTU that was obtained in the negative mode. The only
peak that is evident from the spectra above is the substrate PTU with m/z 169.04
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The presence of a single peak from the solvent-electrolyte mixtures shows that there were
no any other reactions or contaminants prior to the electrochemical oxidation.
Contaminants as well as other reactions in the electrolyte mixture, are usually confused
for modifications that might take place on the compound of interest. As such, any
products that emerged when the reaction was initiated by applying potential could thus be
attributed to transformations due to oxidation of PTU in the electrochemical cell.
When the cell was turned on, the voltage was gradually increased with a ramp of 100
mV each time. There was emergence of additional peaks at 400 mV. This potential was
enough to initiate oxidation of PTU to a disulfide and sulfinic acid, as shown in figure 5.3
below. PTU disulfide was the dominant peak in both acidic and alkaline medium.
However, in acidic medium there were many spurious peaks that could not be easily
assigned to anything.
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Figure 5.3. ESI-MS spectra generated with the cell potential at 400 mV.

Figure 5.3 shows a strong peak of PTU-disulfide, which is the major product of
oxidation at the given potential of 400 mV. Dimeric species from thiols are usually
unreactive compared to parent thiols, hence they accumulate. Surprisingly, the
electrochemical oxidation of PTU was achieved at very low potentials, compared to what
has been reported previously in literature. Sartori et al, reported higher electrode
potentials of 1.42 V for oxidation of PTU to its dimer using cyclic voltammetry.126
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Electrode potential (Em) is pH-dependent, it has been shown that it decreases with
approximately 0.06 V/pH, for a simple thiol such as glutathione. Therefore, as the pH is
increased, the potential required to effect oxidation decreases.127 The data below points
out the possibility of two competing reaction pathways. Thiol oxidation can proceed
through two competing pathways. Abstraction of a single electron is relatively easy
leading to a thiyl radical. The two electron pathway, results in formation of sulfenic acid.
These two intermediates participate in further reactions resulting in metastable
products.128 Thus the thiyl radical might initiate chain reactions that results in a disulfide.
This is a coupled-proton electron transfer process resulting in a radical that dimerizes to a
disulfide as shown in scheme 5.1 below.

Scheme 5.1 Proposed oxidation scheme for PTU and its dimerization to a disulfide
compound.

There is a relatively weak peak at m/z 201 which shows a sulfinic acid. In theory
one would expect to observe the S-oxides of PTU in the mass spectrum. Thiols are
known to undergo oxidation to sulfenic acid which further oxidizes to more stable
sulfinic and sulfonic acids respectively,129,130 as seen in the equation below.
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RSH

RSOH

RSO2H

Thiol

sulfenic acid

sulfinic acid

RSO3H…….. (R5.1)
sulfonic acid

There is no evidence of formation of sulfenic acid, or the S-oxide in the spectrum. The
sulfenic acid may transform to its more stable form of an S-oxide.62 However, sulfenic
acids exhibit potent electrophilic and relative weak nucleophilic reactivity.131 Thus in
small molecules such as PTU, this dual behavior can lead to self-condensation in which
one sulfur atom functions as a nucleophile and the second as an electrophile to yield a
thiolsulfinate ester shown below

….. (R.5.2)

The self-condensation reaction is facilitated by intermolecular hydrogen bonding. At a
pH > 8, which is the case in this series experiments, the thiolsulfinate esters
disproportionate to form salts of sulfinic acid and disulfide.132 This reaction can thus
explain both the presence of sulfinate and the dimer observed in figure 5.3. Trapping
experiments were also conducted in PTU oxidations. Unlike in oxidation of methimazole,
there were no conjugates that formed between PTU and nucleophiles. Presumably the
reaction proceeds through formation of the dimer. This dimer then would further be
oxidized to sulfinic acid. Regardless of which pathway dominates, both mechanisms have
potential to result in reactive intermediates
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5.2.2 Effect of oxidation potential

An analysis of the ESI spectrum collected at higher oxidative potentials of 800
mV shows two additional peaks that were observed on the mass spectrum. Figure 5.4
show that sulfur was fully oxidized, from -2 to +6, to yield sulfate (SO42-) shown, with
m/z 96. Effluent from the cell was reacted with barium chloride, resulting in formation of
BaSO4. There was no evidence of formation of PTU-sulfonic acid from the ESI mass
spectra. Hydrolysis of sulfinic acid, should result in the cleavage of the C=S bond to give
a urea-type residue, R1R2C=O and an unstable sulfur species HSO2- . HSO2- is readily
oxidized to bisulfite (HSO3-).

HSO2- + H2O  HSO3- + 2H+ + 2e-

R5.3

HSO3- is in turn easily hydrolyzed to sulfate. One would expect a significant amount of
the urea type organic residue if hydrolysis was the major pathway. However, only traces
(propyl uracil) at m/z 153 and an unidentified metabolite with m/z 135 were observed. If
this organic residue is not stable; it would further hydrolyze through ring opening giving
small fragments. A decrease of 32 amu, is apparent from the initial mass of substrate.
The exact mechanism from the sulfinic acid to sulfate and an organic residue can only be
speculative, but involves no further oxidation past the formation of sulfate. Non-solvent
assisted cleavage of C-S bond, which is either heterolytic or homolytic cleavage, should
result in loss of sulfur as sulfite and sulfite radical anion respectively from sulfinic
acid.133 The organic residue observed is shown with the peak at m/z of 137, thus this is
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6-propyl-2, 3-dihydropyrimidin-4(1H)-one. The spectrum below still shows the dimer
m/z 168 is the symmetrical PTU dimer.
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Figure 5.4. ESI-MS spectra generated with the cell potential at 800 mV.

The one-electron pathway, resulting in thiyl radicals appears to be the most dominant
mechanism here. Radicals play a very important role in induced oxidative stress and
subsequent liver injury. Waldhauser and co-workers investigated the oxidation of PTU in
activated neutrophils. PTU was observed to be oxidized by myeloperoxidase,110
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resulting in sulfite as one of the products, as indicated above, this can be further oxidized
to sulfate. If PTU desulfurization involve forming sulfite radical, one would expect it to
undergo further reactions which may or may not lead to reactive metabolites.
It has been shown that sulfite and sulfite radicals are oxidized by
myeloperoxidase to free radicals. These prooxidant radicals , such as the reactive sulfur
trioxide (SO3•−), peroxymonosulfate (−O3SOO•), and sulfate (SO4•−) anion radicals have
capacity to damage proteins and oxidize them to protein radicals, with consequences of
allergic reactions.134 Whereas some studies reported that there have been no reactive
metabolites formation in the liver. Some intermediates e.g., 6-propyl-2,3dihydropyrimidin-4(1H)-one , (propyluracil) and other unidentified metabolites, with
prooxidant radicals were echoed in electrochemical system. Some of the intermediates
have been proposed but have not been observed in previous in vivo and in vitro studies.
Radicals can also generate toxic effects through oxidative stress without forming covalent
adducts with biomolecules.135 This forms the basic framework for the danger hypothesis
that leads to idiosyncratic toxicities.

5.3 In vitro enzymatic oxidation of PTU

The metabolism of PTU was studied based on standard in vitro technique,
involving incubation of the target compound with liver microsomes. The experiments
here were performed using human microsomes. The results obtained from the liquid
chromatography separation with mass spectrometry detection are shown in Figure 4.5.
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The oxidation of PTU with microsomes was complex. Identification of the products from
metabolism was complicated by the presence of biological matrix and a range of possible
metabolites.

Figure 5.5. LC-MS chromatograms from metabolites generated by incubation with
human liver microsomes (HLM)
Although not quite abundant figure 5.6 shows spurious peaks on the ESI-spectra,
some of them where unidentified. However, this observation does not really point to an
inferior technique. Instead it does show that a variety of metabolites a possible from
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biological oxidations versus EC-MS. Figure 5.5 shows the chromatogram, extracted from
ion filtering using Xcalibur software. Retention time of the 14.30 peak shows the
unconverted substrate PTU, with m/z 171.13 shown in figure 5.6 below. Another peak
on the chromatogram, with retention time of 5.81 was associated with the unconverted
substrate; this could be due to tautomer of PTU, resulting in a more polar ion form of
PTU. This analysis is further complicated by the appearance of another small peak that
co-eluted at this same retention time. The peak had a jump of 16 amu from the substrate,
thus [M + O + H] with at m/z 186.22, a putative PTU S-oxide. The relatively low
abundance of the peak, appears to show a transient molecule that is derived from unstable
sulfenic, moreover it is fleeting towards sulfinic and sulfonic acids. In this biological
matrix, the reactive sulfenic acid can react with the protein components of microsomes.
Usually after centrifugation, the protein pellet will sediment and is not analyzed in LCMS analysis, hence a diminished peak of the remaining metastable S-oxide can be
observed. Its polarity also fits very well to the assigned retention time.
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Figure 5.6 ESI (+) mass spectrum showing product of oxidation from microsomal
incubation.
Interestingly, hepatotoxicity due to PTU has been known, but it is surprising that, there
have not been a lot of studies dedicated to the oxidation of PTU using microsomes. Most
of the studies conducted used peroxidases as oxidants, and as such, there have not been
known reactive metabolites produced from microsomes. Studies on the oxidation of PTU
with activated neutrophils showed that PTU-disulfide, PTU-sulfite/sulfinic acid, and
PTU-sulfate/sulfonic acid were the major products of oxidation.110. The toxicity of
thionamides, such as ethionamide has been associated with their bioactivation to reactive
S-oxides.136,137 Therefore, hepatotoxicity due to PTU may also arise from the observed S101

oxide; this electrophilic metabolite has the capacity to bind to liver cellular
macromolecules resulting in drug damage to cells.

5.3.1 Oxidation mechanism

Metabolism by microsomes involves primarily the flavin-containing
monooxygenases (FMO’s) and the CYP450 group of enzymes. FMO’s are a family of
drug-metabolizing enzymes that use FAD, NADPH and molecular oxygen to catalyze the
oxygenation of a large number of xenobiotics containing ‘soft’ nucleophiles such as
sulfur, phosphorus and nitrogen.138,139

Scheme 5.2 Proposed reaction scheme for PTU metabolism in microsomes.
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The scheme above shows a simple mechanism for oxidation of PTU in microsomes.
FMOs convert xenobiotics into polar metabolites by adding oxygen so that they can
subsequently be easily eluted through the kidneys.140 While initially thought to be a
single enzyme; FMO’s are now known to contain at least 11 isoforms, with 5 of them
having been characterized to date.141,142 It has been reported that FMOs oxidize
thionamides and thiourea functional groups to intermediate metabolites of sulfenic
(RSOH) and sulfinic (RSO2H) acid which are responsible for deactivating CYP450
enzymes.143,144 As mentioned earlier on, sulfenic acid is a very unstable intermediate,
giving rise to metastable S-oxide. In presence of excess oxidative power, the S-oxide and
sulfinic acid will further be oxidized to sulfonic acid, as shown in scheme 5.2.
The standard procedure for trapping reactive metabolites was also carried out
using glutathione and n-acetyl cysteine as trapping agents. There were no detectable
conjugates, in reactions of PTU. Sulfenic acid precedes formation of S-oxide and is very
reactive to be able to react with thiol. However, even if the intermediates were formed,
their conjugation with nucleophiles is not always spontaneous as in the case of MMIacetylcysteine, sometimes it requires enzymes, such as glutathione transferase which can
facilitate conjugation.
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Figure 5.7 ESI (+) MS spectra showing sulfinic acid and sulfonic acid as products of
oxidation of PTU.

PTU is less polar as compared to its products of oxidation, which co-eluted within
1.95 and 2.06 minutes. Figure 5.7 shows 6-propyl-2-thiouracil sulfinic acid (PTU-SO2H)
m/z 203.04, 6-propyl thiouracil sulfonic acid (PTU-SO3H) m/z 218.94, and its sodium
adduct m/z 240.09 as the major products of microsomal oxidation. These are stable
oxides for oxidation of PTU. PTU-sulfonic acid/sulfonate, at m/z 218.94, [M +3O +H+]
and 240.09, [M +3O +Na+] exist as a zwitterion form before adducted to a proton or
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sodium respectively. Microsomal oxidations were carried out in a pH of 7.4, close to
neutral pH, and thus it can afford such neutral structures. Molecules with such structure
have been observed from X-ray data. Chigwada et al,75 showed the existence of this
putative sulfonic acid zwitterion for tetra methyl thiourea sulfonic acid (TTTU-SO3-),
figure 5.8 a. Figure 5.8 b shows putative the molecular ion as observed in ESI spectrum
at m/z 240.02.

(a)

(b)

Figure 5.8 Putative zwitterion structures

Figure 5.7 shows undefined metabolite at m/z 196.96. This shows some of problems that
arise from microsomal oxidations. The matrix contains different endogenous material
which can co-elute with compounds of interests. Contrary to this, it also shows the
diversity of metabolites that can be obtained from microsomal oxidations.

105

5.3.2 Comparison of electrochemical and biological metabolism.

There were variations in the nature and type of metabolites that have been
observed from electrochemical oxidation of the PTU compared to what has been
observed and reported in biological studies.145 Both Figures 5.6 and 5.7 shows some
unidentified peaks e.g., the peak with m/z 196 could not be assigned to any metabolite in
the mixture. The electrochemical process is a ‘cleaner’ oxidation environment than that
afforded by microsomes. Thus the electrochemical oxidation platform involves the most
easily oxidizable part of the molecule without any regard to other parameters present in
bimolecular activations such as stereochemistry.
Oxidation of thiols through formation of their disulfides is relatively easy,
compared to two electron process for the formation of S-oxide. Contrary to the EC-MS
system, microsomal oxidations show non competing reaction pathways. Successive
formation of sulfo-oxo acids is through a two electron transfer mechanism by FMO Soxygenation. Microsomes contain CYPs as well, which participates in functionalization
reactions; as such one would expect a variety of metabolites. However, there are some
other factors that might prevent this e.g., thionaamides are known to be enzyme
inhibitors,146 this has large bearing on the nature of products that can be obtained from
their biological oxidation using microsomes. The kinetics for the EC-MS two electron
mechanism are quite sluggish. Electron-withdrawing groups such as oxygen in the ring
for PTU may reduce the nucleophilicity nature of S atom on the thiolate ion, making it
difficult to abstract a second electron. A comparison of EC-MS oxidations to microsomal
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oxidations shows there is a physiological gap between the isolated microsomes and
electrochemical cells. Nevertheless, there were similarities in type of metabolites
obtained from EC-MS with those obtained using peroxidase enzymes as indicated earlier
on. Differences in metabolites may be attributed to experimental conditions.

5.5 Conclusion

Bioactivations of sulfur-based drugs have always been difficult to determine.
PTU oxidation is generally complex, characterized by free radical and two electron
process mechanism in electrochemistry and microsomal oxidations respectively. PTU
oxidation resulted in a range of metabolites, the absence of conjugates in either system,
does not preclude formation of reactive metabolites. The kinetics of that step was much
faster, such that the metabolites were not captured. However, results show that an S-oxide
which is electrophilic and hepatotoxic is produced in liver microsomes. Toxicity of PTU
may be attributed to this reactive metabolite. Moreover, the mechanism entails two
pathways which might be involved in toxicity due to PTU. EC-MS techniques
complement the microsomes and is quite informative in evaluation of toxicities from
drugs, as it gives an alternative explanation to observed phenomena.
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